http://www.pharmajournalist.com/conference-co-chairs-invite-medical-devices-experts-to-the-medical-devices-ivd-conference/ 2022-09-23T10:41:46+00:00 https://pharmajournalist.com/wp-content/uploads/2022/08/P-385-Medical-Devices-2022-650x650-.jpg http://www.pharmajournalist.com/co-chairs-invitation-to-attend-the-pharmaceutical-cleanrooms-conference-in-london-uk/ 2022-09-26T09:27:57+00:00 https://pharmajournalist.com/wp-content/uploads/2022/09/P-383-Pharmaceutical-Cleanroom-2022-1200x627-copy.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/09/P-383-Pharmaceutical-Cleanroom-2022-1200x627-copy.jpg http://www.pharmajournalist.com/pheon-therapeutics-launches-with-68-million-in-financing-to-advance-novel-antibody-drug-conjugates-for-treatment-of-solid-tumors/ 2022-09-30T07:16:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/verismo-therapeutics-receives-fda-orphan-drug-designation-for-synkir-110-a-first-in-class-kir-car-t-cell-immunotherapy-candidate-for-the-treatment-of-mesothelioma/ 2022-09-30T07:18:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer/ 2022-09-30T07:19:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/Scribe-Therapeutics-Logo.jpg http://www.pharmajournalist.com/mercks-keytruda-pembrolizumab-receives-four-new-approvals-in-japan-including-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc/ 2022-09-30T07:21:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/emergent-biosolutions-completes-acquisition-of-exclusive-worldwide-rights-to-tembexa-brincidofovir-the-first-fda-approved-smallpox-oral-antiviral-for-all-ages/ 2022-09-30T07:23:49+00:00 https://pharmajournalist.com/wp-content/uploads/2022/09/Emergent-Bio.jpg http://www.pharmajournalist.com/seagen-and-lava-therapeutics-announce-exclusive-worldwide-license-agreement-to-advance-lava-1223/ 2022-09-30T07:25:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizer-and-biontech-submit-application-to-fda-for-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-bivalent-vaccine-booster-in-children-5-through-11-years-of-age/ 2022-09-30T07:27:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/ultomiris-approved-in-europe-for-the-treatment-of-adults-with-generalised-myasthenia-gravis/ 2022-09-30T07:28:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/u-s-district-court-rules-in-favor-of-merck-in-sitagliptin-phosphate-patent-lawsuit/ 2022-09-30T07:30:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/almirall-and-simcere-enter-into-a-licensing-agreement-for-il-2-mu-fc/ 2022-09-30T07:31:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Almirall_Plant_Reinbek.jpg http://www.pharmajournalist.com/mckesson-corporation-extends-pharmaceutical-distribution-agreement-with-cvs-health/ 2022-09-30T07:33:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/thermo-fisher-scientific-launches-a-more-sustainable-solution-for-large-scale-cell-culture-harvesting/ 2022-09-30T07:34:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas-in-neurofibromatosis-type-1/ 2022-09-30T07:38:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/pulse-biosciences-announces-fda-510k-clearance-for-the-treatment-of-sebaceous-hyperplasia/ 2022-09-30T07:39:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/atamyo-therapeutics-announces-first-patient-dosed-with-ata-100-gene-therapy-in-lgmd-r9-clinical-trial/ 2022-09-30T07:40:51+00:00 http://www.pharmajournalist.com/massive-bio-continues-to-grow-in-europe/ 2022-09-30T07:42:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/visus-therapeutics-expands-ophthalmic-drug-development-portfolio-with-acquisition-of-viewpoint-therapeutics-assets/ 2022-09-30T07:43:21+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-nodularis/ 2022-09-30T07:44:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/arsenal-biosciences-announces-joint-discovery-collaboration-with-genentech-to-identify-features-of-successful-t-cell-therapies-for-oncology/ 2022-09-30T07:46:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sciwind-biosciences-and-synerk-enter-into-research-partnership-to-discover-and-develop-novel-sirna-therapeutics/ 2022-09-30T07:48:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lynparza-approved-in-china-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer/ 2022-09-30T07:49:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/intravacc-awarded-us14-6-million-nih-niaid-contract-to-develop-intranasal-gonorrhea-vaccine/ 2022-10-07T07:30:59+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pfizer-completes-acquisition-of-global-blood-therapeutics/ 2022-10-07T07:32:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/biolink-life-sciences-charak-foundation-and-kare-biosciences-announce-contract-for-developing-a-novel-treatment-of-covid-pneumonia-and-prevention-of-long-covid/ 2022-10-07T07:33:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/biogen-and-denali-therapeutics-announce-initiation-of-the-phase-3-lighthouse-study-in-parkinsons-disease-associated-with-lrrk2-pathogenic-mutations/ 2022-10-07T07:35:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/mirecule-enters-into-strategic-collaboration-with-sanofi-to-accelerate-discovery-and-development-of-a-best-in-class-antibody-rna-conjugate-to-treat-facioscapulohumeral-muscular-dystrophy-fshd/ 2022-10-07T07:37:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/ 2022-10-07T07:38:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/shionogi-and-the-medicines-patent-pool-mpp-sign-licence-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-increase-access-in-low-and-middle-income-countries/ 2022-10-07T07:39:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/shionogi-logo.jpg http://www.pharmajournalist.com/myovant-sciences-special-committee-of-board-confirms-receipt-of-preliminary-non-binding-proposal-from-sumitovant-biopharma-and-sumitomo-pharma-to-acquire-remaining-shares/ 2022-10-07T07:41:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/amylyx-pharmaceuticals-announces-fda-approval-of-relyvrio-for-the-treatment-of-als/ 2022-10-07T07:43:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ventus-therapeutics-enters-exclusive-development-and-license-agreement-with-novo-nordisk-for-nlrp3-inhibitor-program/ 2022-10-07T07:45:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/inflarx-submits-request-for-emergency-use-authorization-to-us-fda-for-vilobelimab-for-treatment-of-critically-ill-covid-19-patients/ 2022-10-07T07:46:59+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/inflarx-logo.png http://www.pharmajournalist.com/amplifybio-acquires-pact-pharma-assets-to-enhance-cell-and-gene-therapy-characterization-capabilities/ 2022-10-07T07:49:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lineage-establishes-new-rd-facility-in-u-s-and-expands-current-gmp-manufacturing-facility-in-israel/ 2022-10-07T07:51:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/Lineage_Logo.png http://www.pharmajournalist.com/alexion-astrazeneca-rare-disease-to-acquire-logicbio-therapeutics-to-accelerate-growth-in-genomic-medicine/ 2022-10-07T07:53:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/myonex-completes-acquisition-of-hubertus-clinical-trial-and-packaging-business/ 2022-10-07T07:54:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/merck-and-ridgeback-biotherapeutics-provide-update-on-new-clinical-and-non-clinical-studies-of-lagevrio-molnupiravir/ 2022-10-07T08:05:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/tempus-announces-companion-diagnostic-collaboration-with-kartos-therapeutics/ 2022-10-07T08:07:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/personalis-forms-research-collaboration-to-better-predict-immunotherapy-response-for-gastroesophageal-cancer/ 2022-10-07T08:15:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/vanda-pharmaceuticals-and-olipass-announce-strategic-partnership-to-develop-antisense-oligonucleotide-therapeutics/ 2022-10-07T08:16:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/cepi-partners-with-intravacc-to-develop-an-intranasal-broadly-protective-betacoronavirus-vaccine/ 2022-10-07T08:18:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/cytiva-strengthens-cell-line-development-with-cevec-acquisition/ 2022-10-07T08:20:35+00:00 https://pharmajournalist.com/wp-content/uploads/2021/09/image_1.jpg http://www.pharmajournalist.com/enzo-biochem-inc-opens-expanded-life-sciences-laboratory-and-office-facilities-in-farmingdale-new-york/ 2022-10-07T08:21:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Enzo-logo.jpg http://www.pharmajournalist.com/almac-unveils-new-cryogenic-service-solution-for-advanced-therapy-trials/ 2022-10-07T08:23:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/HSA-Inspection_Almac-Group.jpg http://www.pharmajournalist.com/milliporesigma-announces-a-boost-in-commercial-capacity-in-france-as-part-of-new-millipore-ctdmo-services/ 2022-10-07T08:25:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/MilliporeSigma.jpg http://www.pharmajournalist.com/registration-is-now-open-for-pre-filled-syringes-and-injectable-drug-devices-conference-in-europe/ 2022-10-07T08:44:38+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Pre-Filled-Syringes-Europe-2023-PR.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/10/Pre-Filled-Syringes-Europe-2023-PR.jpg http://www.pharmajournalist.com/many-delegates-already-registered-for-transdermal-and-microneedle-drug-delivery-conference-in-london/ 2022-10-07T09:13:57+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Transdermal-and-Microneedle-drug-Delivery-PR.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/10/Transdermal-and-Microneedle-drug-Delivery-PR.jpg http://www.pharmajournalist.com/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine/ 2022-10-14T10:21:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/vita-therapeutics-closes-31-million-series-b-financing-to-develop-cell-therapies-for-neuromuscular-diseases-and-cancers/ 2022-10-14T10:22:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/inceptor-bio-and-avectas-announce-collaboration-to-improve-manufacturing-of-car-t-cell-therapies-for-the-treatment-of-solid-tumors/ 2022-10-14T10:23:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/oncotelic-awarded-barda-funding-for-development-of-ot-101-for-long-covid/ 2022-10-14T10:25:27+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/nimbus-therapeutics-announces-research-collaboration-and-license-agreement-with-lilly-for-small-molecule-activators-of-ampk/ 2022-10-14T10:26:49+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/neumora-therapeutics-announces-112-million-series-b-financing/ 2022-10-14T10:27:53+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/wuxi-biologics-and-toregem-biopharma-sign-mou-for-development-of-anti-usag-1-antibody/ 2022-10-14T10:30:04+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/photo-scaled-1.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/10/photo-scaled-1.jpg http://www.pharmajournalist.com/stalicla-to-in-license-sfx-01-from-evgen-for-neurodevelopmental-disorder-indications/ 2022-10-14T10:32:49+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/STALICLA-Logo.jpg http://www.pharmajournalist.com/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-retinitis-pigmentosa/ 2022-10-14T10:35:07+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Nanoscope_Therapeutics_Logo.jpg http://www.pharmajournalist.com/ochre-bio-raises-30m-series-a-financing-for-the-development-of-rna-therapies-for-chronic-liver-diseases/ 2022-10-14T10:37:51+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Ochre-Bio-Co-Founders-Quin-Wills.jpg https://pharmajournalist.com/wp-content/uploads/2022/10/Ochre-Bio-Co-Founders-Quin-Wills.jpg http://www.pharmajournalist.com/fda-approves-boostrix-for-immunisation-during-pregnancy-for-the-prevention-of-whooping-cough-in-newborn-infants/ 2022-10-14T10:39:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/the-china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers/ 2022-10-14T10:41:05+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/innovent-biologics-logo.png http://www.pharmajournalist.com/sanofi-us-enters-into-co-promotion-agreement-with-provention-bio-inc-to-launch-teplizumab-an-investigational-disease-modifying-therapy-for-type-1-diabetes/ 2022-10-14T10:42:23+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/lilly-receives-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-comorbidities/ 2022-10-14T10:43:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/surrozen-announces-strategic-partnership-with-boehringer-ingelheim-to-develop-wnt-agonist-szn-413-for-people-with-retinal-diseases/ 2022-10-14T10:45:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/intravacc-awarded-us14-6-million-nih-niaid-contract-to-develop-intranasal-gonorrhea-vaccine-2/ 2022-10-14T10:47:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/xcell-biosciences-and-acgt-vector-collaborate-to-accelerate-development-of-cell-and-gene-therapies/ 2022-10-14T10:48:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pandemic-response-lab-launches-novel-triple-target-monkeypox-tests/ 2022-10-14T10:50:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/tavros-therapeutics-and-vividion-therapeutics-announce-strategic-collaboration-to-discover-and-enhance-targeted-oncology-programs/ 2022-10-14T10:51:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pasithea-therapeutics-acquires-allomek-therapeutics/ 2022-10-14T10:52:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ginkgo-bioworks-announces-collaboration-with-merck-to-improve-active-pharmaceutical-ingredient-manufacturing/ 2022-10-14T10:54:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/bluestar-genomics-receives-cap-accreditation-for-its-clinical-laboratory/ 2022-10-14T10:55:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-launches-ce-ivd-marked-panel-to-detect-most-common-gastrointestinal-bacteria/ 2022-10-14T10:56:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/tempus-announces-companion-diagnostic-collaboration-with-kartos-therapeutics-2/ 2022-10-14T10:59:04+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/logo_tempus.jpg http://www.pharmajournalist.com/sisafs-innovative-rna-therapeutic-for-rare-genetic-skeletal-disorders-begins-the-u-s-regulatory-process-for-orphan-drug-designation/ 2022-10-14T11:01:37+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/cssi-lifesciences.png http://www.pharmajournalist.com/eligo-bioscience-receives-fda-orphan-drug-designation-odd-and-rare-pediatric-disease-rpd-designation-for-eb003-for-the-prevention-of-hemolytic-uremic-syndrome-with-first-in-class-crispr-based-medi/ 2022-10-14T11:02:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-acquires-djs-antibodies-further-strengthening-immunology-pipeline/ 2022-10-21T09:08:33+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/advaxis-and-ayala-pharmaceuticals-enter-into-merger-agreement/ 2022-10-21T09:09:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-as-a-booster-for-adults/ 2022-10-21T09:13:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/syncromune-enters-into-an-exclusive-worldwide-license-agreement-with-eucure-biopharma-co-ltd-to-develop-and-commercialize-yh002-ox40-antibody-and-two-undisclosed-active-ingredients-as-components/ 2022-10-21T09:19:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lilly-to-acquire-akouos-to-discover-and-develop-treatments-for-hearing-loss/ 2022-10-21T09:21:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/oculis-sa-and-european-biotech-acquisition-corp-announce-business-combination-agreement-to-create-nasdaq-listed-biopharmaceutical-company-driving-breakthrough-innovations-in-ophthalmology/ 2022-10-21T09:23:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gilead-and-macrogenics-announce-oncology-collaboration-to-develop-bispecific-antibodies/ 2022-10-21T09:26:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/novo-nordisk-announces-the-completion-of-the-forma-therapeutics-acquisition/ 2022-10-21T09:27:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/chmp-recommends-conditional-marketing-authorization-for-spesolimab-as-first-in-class-treatment-option-for-generalized-pustular-psoriasis-flares/ 2022-10-21T09:30:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/amgen-successfully-completes-acquisition-of-chemocentryx/ 2022-10-21T09:31:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/ginkgo-bioworks-completes-acquisition-of-zymergen/ 2022-10-21T09:33:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/telesis-bio-and-cellibre-announce-collaboration-to-optimize-development-of-future-bioxp-dbc-instrument/ 2022-10-21T09:39:59+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/verseon-acquires-edammo/ 2022-10-21T09:41:03+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/immune-onc-therapeutics-initiates-expansion-cohorts-for-io-108-and-enters-into-clinical-supply-agreement-with-regeneron/ 2022-10-21T09:42:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/imaginab-and-cyclotek-enter-into-manufacturing-and-distribution-agreement-for-cd8-immunopet-agent-in-australia/ 2022-10-21T09:44:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/ImaginAb-Logo.jpg http://www.pharmajournalist.com/zymeworks-to-host-conference-call-on-exclusive-licensing-agreement-of-zanidatamab/ 2022-10-21T09:46:10+00:00 https://pharmajournalist.com/wp-content/uploads/2019/01/ZymeWorks-Logo.png http://www.pharmajournalist.com/charles-river-and-nanoscope-therapeutics-announce-multifaceted-gene-therapy-manufacturing-partnership/ 2022-10-21T09:47:38+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/kites-yescarta-first-car-t-cell-therapy-to-receive-european-marketing-authorization-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma/ 2022-10-21T09:49:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/bavarian-nordic-enters-agreement-with-switzerland-on-the-supply-of-smallpox-and-monkeypox-vaccine/ 2022-10-21T09:51:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/catalent-expands-biologics-analytical-capabilities-with-new-laboratories-at-center-of-excellence-in-kansas-city-missouri/ 2022-10-21T09:55:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Catalent-Logo.png http://www.pharmajournalist.com/takeda-enters-collaboration-and-licensing-agreement-with-zedira-and-dr-falk-pharma-to-develop-first-in-class-celiac-disease-therapy/ 2022-10-21T09:56:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/corium-and-gurnet-point-capital-announce-manufacturing-business-acquisition-and-a-100-million-neuroscience-therapeutics-investment-by-webster-equity-partners-establishing-two-independent-growth-comp/ 2022-10-21T09:58:17+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pic-therapeutics-completes-35-million-series-a-financing-to-develop-treatments-for-drug-resistant-breast-cancer/ 2022-10-21T10:10:46+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/registration-is-now-open-for-rna-therapeutics-conference-2023/ 2022-10-25T10:48:23+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/P-393-RNA-Therapeutics-2023-300-x-250-copy.jpg http://www.pharmajournalist.com/co-chairs-from-aerie-pharmaceuticals-santen-inc-usa-invite-industry-experts-to-join-ophthalmic-drugs/ 2022-10-27T12:12:36+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Ophthalmic-Drug-2022-SMi-Group.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/10/Ophthalmic-Drug-2022-SMi-Group.jpg http://www.pharmajournalist.com/2seventy-bio-and-jw-therapeutics-announce-strategic-partnership-to-accelerate-the-research-and-development-of-t-cell-based-immunotherapies/ 2022-10-28T10:41:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/seres-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-investigational-microbiome-therapeutic-ser-109-for-recurrent-c-difficile-infection-for-priority-review/ 2022-10-28T10:43:05+00:00 https://pharmajournalist.com/wp-content/uploads/2021/07/Seres-Therapeutics.jpg http://www.pharmajournalist.com/health-canada-approves-kerendia-finerenone-as-an-adjunct-to-standard-of-care-therapy-in-adults-with-chronic-kidney-disease-ckd-and-type-2-diabetes-t2d/ 2022-10-28T10:45:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/sk-bioscience-and-cepi-sign-agreement-to-develop-mrna-vaccines/ 2022-10-28T10:47:44+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/SK_bioscience_and_CEPI.jpg https://pharmajournalist.com/wp-content/uploads/2022/10/SK_bioscience_and_CEPI.jpg http://www.pharmajournalist.com/fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/ 2022-10-28T10:50:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/astellas-and-taysha-gene-therapies-announce-strategic-investment-to-support-development-of-tayshas-aav-based-gene-therapy-programs/ 2022-10-28T10:52:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/imjudo-tremelimumab-in-combination-with-imfinzi-approved-in-the-us-for-patients-with-unresectable-liver-cancer/ 2022-10-28T10:53:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/biomed-x-inks-research-collaboration-with-sanofi-on-artificial-intelligence-for-drug-development/ 2022-10-28T10:54:53+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/european-medicines-agency-validates-viiv-healthcares-marketing-authorisation-application-for-cabotegravir-long-acting-injectable-for-hiv-prevention/ 2022-10-28T10:56:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/ViiV-Healthcare.png http://www.pharmajournalist.com/hookipa-announces-strategic-collaboration-and-license-agreement-with-roche-to-develop-novel-arenaviral-immunotherapy-for-kras-mutated-cancers/ 2022-10-28T10:58:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/rinvoq-upadacitinib-receives-its-sixth-u-s-fda-approval/ 2022-10-28T11:00:03+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/ptc-therapeutics-announces-strategic-financing-collaboration-with-blackstone-with-up-to-1-billion-in-funding/ 2022-10-28T11:01:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/PTC-Therapeutics.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-to-expand-clinical-research-laboratory-in-kentucky/ 2022-10-28T11:02:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/novaccess-global-receives-fda-approval-of-orphan-drug-application-for-tlr-ad1/ 2022-10-28T11:03:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/telix-and-uniquest-to-collaborate-on-radiolabelled-immune-targeting-peptide/ 2022-10-28T11:05:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/wuxi-biologics-announces-gmp-release-of-48000l-commercial-drug-substance-manufacturing-facility-in-hebei-china/ 2022-10-28T11:06:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/sumitovant-biopharma-sumitomo-pharma-and-myovant-sciences-enter-into-definitive-agreement/ 2022-10-28T11:11:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ariceum-therapeutics-and-ambiopharm-enter-strategic-manufacturing-and-supply-partnership/ 2022-10-28T11:13:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/csl-enters-into-strategic-option-and-license-agreement-with-translational-sciences/ 2022-10-28T11:15:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/normunity-announces-65-million-series-a-financing-to-expand-the-frontier-of-precision-immuno-oncology-with-immune-normalizer-therapies/ 2022-10-28T11:16:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/quizartinib-granted-priority-review-in-the-u-s-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia/ 2022-10-28T11:27:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/ars-pharmaceuticals-announces-fda-acceptance-of-nda-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis/ 2022-10-28T11:31:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kite-and-refuge-biotechnologies-announce-exclusive-license-agreement-for-investigational-gene-expression-platform-for-blood-cancers/ 2022-10-28T11:32:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/fujifilm-diosynth-biotechnologies-and-roosterbio-announce-collaboration-to-enable-gmp-manufacturing-of-cell-and-exosome-therapies/ 2022-10-28T11:35:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Fujifilm.jpg http://www.pharmajournalist.com/emalex-biosciences-announces-250-million-financing-round-to-advance-investigational-new-drug-for-tourette-syndrome/ 2022-11-04T11:16:57+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-vemlidy-tenofovir-alafenamide-for-treatment-of-chronic-hepatitis-b-virus-infection-in-pediatric-patients/ 2022-11-04T11:18:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19/ 2022-11-04T11:19:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/ascletis-announces-u-s-ind-filing-of-oral-3clpro-inhibitor-asc11-for-covid-19/ 2022-11-04T11:21:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ascletis-logo.jpg http://www.pharmajournalist.com/dyne-therapeutics-receives-fda-fast-track-designation-for-dyne-251-for-the-treatment-of-duchenne-muscular-dystrophy/ 2022-11-04T11:22:27+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Dyne-Therapeutics-Logo.jpg http://www.pharmajournalist.com/intrinsic-medicine-and-phoenix-biotech-acquisition-corp-announce-merger-agreement-to-create-public-company-leveraging-human-milk-biology-to-treat-gut-brain-axis-disorders/ 2022-11-04T11:24:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/karyopharm-and-menarini-group-announce-orphan-medicinal-product-designation-from-the-european-commission-for-selinexor-for-the-treatment-of-myelofibrosis/ 2022-11-04T11:25:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/karyopharma-logo.png http://www.pharmajournalist.com/abbvie-announces-submissions-of-regulatory-applications-for-epcoritamab-duobody-cd3xcd20-for-the-treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-and-large-b-cell-lymphoma-lbc/ 2022-11-04T11:26:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/ 2022-11-04T11:27:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/positive-topline-phase-iii-results-show-roches-vabysmo-improved-vision-for-people-living-with-retinal-vein-occlusion-rvo/ 2022-11-04T11:29:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/innocare-announces-first-adolescent-patient-dosed-in-clinical-trial-of-pan-trk-inhibitor-icp-723-in-china/ 2022-11-04T11:34:29+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Innocare-Logo.png http://www.pharmajournalist.com/thermo-fisher-scientific-to-acquire-the-binding-site-group/ 2022-11-04T11:35:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/biofrontera-inc-enters-into-agreements-to-purchase-options-of-biofrontera-ag/ 2022-11-04T11:47:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/exelixis-and-catalent-enter-into-new-license-agreement-for-three-antibody-drug-conjugate-programs-with-the-potential-to-accelerate-exelixis-biologics-pipeline/ 2022-11-04T11:49:43+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Exelixis.jpg http://www.pharmajournalist.com/exelixis-and-sairopa-establish-exclusive-clinical-development-collaboration-and-option-agreement-to-develop-adu-1805-a-potentially-best-in-class-monoclonal-antibody-targeting-sirp%ce%b1/ 2022-11-04T11:51:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Exelixis.jpg http://www.pharmajournalist.com/csl-enters-licensing-agreement-with-arcturus-therapeutics-for-next-generation-mrna-vaccine-technology/ 2022-11-04T11:54:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/novo-holdings-acquires-kabafusion/ 2022-11-04T11:57:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/evotec-completes-acquisition-of-central-glass-germany/ 2022-11-04T12:00:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/sinovac-varicella-vaccine-prequalified-by-who/ 2022-11-04T12:01:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Sinovac-Biotech-Logo.jpg http://www.pharmajournalist.com/amneal-receives-fda-approval-for-leuprolide-acetate-injection/ 2022-11-04T12:02:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/reithera-expands-large-scale-viral-vector-production-capabilities-with-opening-of-new-manufacturing-facility/ 2022-11-04T12:05:10+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/bioreactor.jpg https://pharmajournalist.com/wp-content/uploads/2022/11/bioreactor.jpg http://www.pharmajournalist.com/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-marginal-zone-lymphoma/ 2022-11-04T12:06:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/pharmather-enters-into-exclusive-option-agreement-with-case-western-reserve-university-to-develop-and-commercialize-ketamine-for-rett-syndrome/ 2022-11-04T12:08:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/almirall-announces-ema-acceptance-for-filing-of-marketing-authorization-application-maa-for-lebrikizumab-in-atopic-dermatitis/ 2022-11-04T12:14:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Almirall_Plant_Reinbek.jpg http://www.pharmajournalist.com/ariceum-therapeutics-and-ambiopharm-enter-strategic-manufacturing-and-supply-partnership-2/ 2022-11-04T12:15:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/kineret-authorised-for-emergency-use-by-fda-for-the-treatment-of-covid-19-related-pneumonia/ 2022-11-11T08:13:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/sobi.jpg http://www.pharmajournalist.com/royalty-pharma-agrees-to-acquire-royalty-interest-in-olpasiran-from-arrowhead-for-250-million-and-future-milestones/ 2022-11-11T08:14:55+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/nrg-therapeutics-announces-16-million-series-a-to-advance-mitochondrial-therapeutics-for-parkinsons-and-als/ 2022-11-11T08:16:16+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-ba-4-ba-5-adapted-bivalent-covid-19-vaccine-booster-for-children-5-through-11-years-of-age-in-european-union/ 2022-11-11T08:17:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/prophase-labs-announces-collaboration-with-dana-farber-cancer-institute/ 2022-11-11T08:21:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/cyagen-and-neurophth-enter-global-strategic-collaboration-to-develop-ai-designed-aav-gene-therapy-vectors-for-ophthalmic-disorders/ 2022-11-11T08:23:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fulgent-genetics-acquires-fulgent-pharma-creating-a-new-paradigm-in-precision-medicine-for-the-company/ 2022-11-11T08:26:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nkgen-biotech-announces-collaboration-with-the-parkinsons-foundation-to-bring-its-novel-natural-killer-cell-therapy-to-the-clinic-for-advanced-parkinsons-disease/ 2022-11-11T08:29:06+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/NKGen-Biotech.jpg http://www.pharmajournalist.com/european-commission-grants-first-approval-worldwide-of-beyfortus-nirsevimab-for-prevention-of-rsv-disease-in-infants/ 2022-11-11T08:30:50+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/reaction-biology-and-vyant-bio-announce-closing-of-definitive-agreement-to-acquire-u-s-operations-of-vyant-bio-inc-subsidiary/ 2022-11-11T08:32:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bayer-acquires-german-biotech-start-up-targenomix/ 2022-11-11T08:35:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/nephron-and-sharps-announce-manufacturing-and-research-partnership/ 2022-11-11T08:36:20+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sanofi-and-gsks-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-the-european-commission/ 2022-11-11T08:37:31+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/sun-pharma-and-sparc-enter-into-a-license-agreement-for-commercialization-of-phenobarbital-for-injection-in-the-us/ 2022-11-11T08:40:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/SunPharma.jpg http://www.pharmajournalist.com/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-hbr/ 2022-11-11T08:41:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bruker-announces-acquisition-of-inscopix-for-neuroscience-research/ 2022-11-11T08:43:21+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/inscopix-pr-image.png https://pharmajournalist.com/wp-content/uploads/2022/11/inscopix-pr-image.png http://www.pharmajournalist.com/mauna-kea-technologies-and-tasly-pharmaceutical-announce-the-incorporation-of-joint-venture-in-china/ 2022-11-11T08:53:14+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/Mauna-Kea-Technologies.png http://www.pharmajournalist.com/hexvix-a-diagnostic-drug-for-bladder-cancer-of-asieris-completed-the-first-patient-dose-in-phase-iii-trial/ 2022-11-11T08:54:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/mhra-grants-approval-of-beyfortusnirsevimab-for-prevention-of-rsv-disease-in-infants/ 2022-11-11T08:57:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/MHRA.jpg http://www.pharmajournalist.com/iti-receives-fda-fast-track-designation-for-iti-3000/ 2022-11-11T09:09:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/Immunomic-Therapeutics-Logo.jpg http://www.pharmajournalist.com/navrogen-enters-into-crada-with-the-u-s-national-cancer-institute-for-the-clinical-development-of-nav-001-an-anti-mesothelin-antibody-drug-conjugate/ 2022-11-11T09:11:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/amgen-presents-new-phase-2-data-that-show-olpasiran-delivers-significant-reduction-in-lipoproteina-levels/ 2022-11-11T09:15:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/salipro-biotech-enters-into-collaboration-and-license-agreement-with-sanofi-to-advance-discovery-programs/ 2022-11-11T09:17:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-nsclc/ 2022-11-11T09:28:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ascletis-announces-ind-approval-of-oral-pd-l1-small-molecule-inhibitor-asc61-for-treatment-of-advanced-solid-tumors-by-china-nmpa/ 2022-11-18T07:52:25+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ascletis-logo.jpg http://www.pharmajournalist.com/phase-3-trial-of-iclusig-ponatinib-met-primary-endpoint-in-newly-diagnosed-ph-all-a-setting-with-no-targeted-treatments-approved-in-the-us/ 2022-11-18T07:54:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/horizon-therapeutics-plc-announces-scientific-collaboration-with-leading-research-institution-to-advance-research-in-autoimmunity-and-inflammation/ 2022-11-18T07:55:31+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/Horizon-Therapeutics-Logo.jpg http://www.pharmajournalist.com/nextcure-and-legochem-biosciences-enter-into-collaboration-and-co-development-agreement-to-develop-antibody-drug-conjugates/ 2022-11-18T07:56:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/elevatebio-and-affini-t-therapeutics-announce-partnership-to-advance-affini-ts-t-cell-therapy-programs-targeting-core-oncogenic-drivers/ 2022-11-18T07:58:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/jnana-therapeutics-announces-second-collaboration-with-roche-to-address-challenging-to-drug-targets-in-cancer-immune-mediated-and-neurological-diseases/ 2022-11-18T07:59:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/indivior-to-acquire-opiant-pharmaceuticals/ 2022-11-18T08:01:19+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Indivior-logo.png http://www.pharmajournalist.com/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments/ 2022-11-18T08:02:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/Exscientia-Logo.png http://www.pharmajournalist.com/immunogen-announces-fda-accelerated-approval-of-elahere-mirvetuximab-soravtansine-gynx-for-the-treatment-of-platinum-resistant-ovarian-cancer/ 2022-11-18T08:04:32+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Immunogen-Logo.png http://www.pharmajournalist.com/biontech-expands-global-footprint-by-acquiring-gmp-manufacturing-site-to-establish-first-mrna-facility-in-singapore/ 2022-11-18T08:05:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/oncopeptides-pepaxti-has-been-granted-marketing-authorization-in-the-uk/ 2022-11-18T08:08:06+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/oncopeptides.gif http://www.pharmajournalist.com/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer/ 2022-11-18T08:10:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer/ 2022-11-18T08:11:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer/ 2022-11-18T08:12:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/sanofi-and-gsks-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-the-european-commission-2/ 2022-11-18T08:14:14+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/royalty-pharma-agrees-to-acquire-royalty-interest-in-olpasiran-from-arrowhead-for-250-million-and-future-milestones-2/ 2022-11-18T08:15:37+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/regeneron-and-cytomx-announce-strategic-research-collaboration-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer/ 2022-11-18T18:29:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/iveric-bio-announces-fda-has-granted-breakthrough-therapy-designation-for-avacincaptad-pegol-for-geographic-atrophy/ 2022-11-18T08:19:31+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/IVERIC_bio.jpg http://www.pharmajournalist.com/roche-receives-u-s-fda-emergency-use-authorization-for-its-high-throughput-test-to-detect-monkeypox-virus/ 2022-11-18T08:20:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/alexion-astrazeneca-rare-disease-completes-acquisition-of-logicbio-therapeutics/ 2022-11-18T08:22:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/ferring-pharmaceuticals-and-gubra-announce-collaboration-within-inflammatory-bowel-disease-ibd/ 2022-11-18T08:23:49+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Ferring-Pharmaceuticals-Singapore.jpg http://www.pharmajournalist.com/idorsia-and-simcere-enter-into-a-licensing-agreement-for-daridorexant-in-china/ 2022-11-18T08:25:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/relief-therapeutics-holding-sa-and-nrx-pharmaceuticals-inc-announce-execution-of-definitive-settlement-agreements/ 2022-11-18T08:26:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/teva-announces-unique-collaboration-with-rimidi-to-expand-the-reach-of-its-respiratory-digital-health-platform/ 2022-11-18T08:27:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/telix-acquires-optimal-tracers/ 2022-11-18T08:28:41+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/nuance-pharma-announces-clearance-of-ind-application-for-respiratory-syncytial-virus-rsv-vaccine-in-china/ 2022-11-18T08:30:40+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/NUANCE_PHARMA_Logo.jpg http://www.pharmajournalist.com/meet-astrazeneca-johnson-johnson-eli-lily-and-more-at-the-14th-annual-rna-therapeutics-conference-2023/ 2022-11-23T03:01:53+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/P-393-RNA-Therapeutics-2023-300-x-250-copy.jpg http://www.pharmajournalist.com/biocytogen-enters-into-antibody-agreement-with-adc-therapeutics/ 2022-11-28T10:16:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sirona-biochem-signs-international-partnership-agreement-with-wanbang-biopharmaceuticals/ 2022-11-28T10:18:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fujifilm-invests-188-million-in-new-cell-culture-media-manufacturing-facility/ 2022-11-28T10:20:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/Fujifilm.jpg http://www.pharmajournalist.com/exploring-the-implementation-of-complex-in-vitro-models-for-drug-development/ 2022-11-28T10:35:19+00:00 https://pharmajournalist.com/wp-content/uploads/2022/11/P-392-3D-Cell-Culture.jpg http://www.pharmajournalist.com/digital-healths-next-five-years-predictions-from-ascension-humana-and-more/ 2022-12-02T08:15:58+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/Digital-Health-Press-Release.png http://www.pharmajournalist.com/wp-content/uploads/2022/12/Digital-Health-Press-Release.png http://www.pharmajournalist.com/roche-canada-announces-purchase-agreement-with-the-government-of-canada-for-actemra-iv-tocilizumab-for-injection-for-treatment-of-adult-patients-with-covid-19/ 2022-12-02T09:13:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/liminatus-pharma-llc-and-iris-acquisition-corp-to-combine-to-incorporate-and-accelerate-much-needed-cancer-treatments/ 2022-12-02T09:15:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biocon-biologics-completes-acquisition-of-viatris-global-biosimilars-business/ 2022-12-02T09:17:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/biocon.jpg http://www.pharmajournalist.com/european-commission-grants-expanded-marketing-authorization-for-gileads-biktarvy-for-the-treatment-of-hiv-in-pediatric-populations/ 2022-12-02T09:19:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/city-of-hope-scientists-develop-new-potential-treatment-for-brain-tumors/ 2022-12-02T09:20:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/City-Of-hope.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy/ 2022-12-02T09:21:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic/ 2022-12-02T09:23:37+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Ferring-Pharmaceuticals-Singapore.jpg http://www.pharmajournalist.com/full-life-technologies-to-acquire-focus-x-therapeutics-bolstering-peptide-focused-radiopharmaceutical-pipeline/ 2022-12-02T09:38:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/c4xd-signs-exclusive-global-licence-worth-up-to-402-million-with-astrazeneca-for-the-development-and-commercialisation-of-nrf2-activator-programme/ 2022-12-02T09:42:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/xtalpi-and-ck-life-sciences-to-collaborate-in-ai-empowered-tumour-vaccine-research-and-development-opening-a-new-paradigm-for-scientific-innovation/ 2022-12-02T09:46:15+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/xtalpi-logo.png http://www.pharmajournalist.com/xeris-biopharma-announces-research-collaboration-and-option-agreement-with-horizon-therapeutics-plc-for-xeriject-formulation-of-teprotumumab/ 2022-12-02T09:48:10+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Xeris-Logo.jpg http://www.pharmajournalist.com/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-active-crohns-disease/ 2022-12-02T09:50:49+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-approves-csls-hemgenix-etranacogene-dezaparvovec-drlb-the-first-gene-therapy-for-hemophilia-b/ 2022-12-28T09:51:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/CSL-Behring.png http://www.pharmajournalist.com/biontech-and-ryvu-therapeutics-enter-into-global-collaboration-to-develop-and-commercialize-immuno-modulatory-small-molecule-candidates/ 2022-12-02T09:53:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/08/BioNTech-AG.jpg http://www.pharmajournalist.com/argenx-enters-into-agreement-to-acquire-priority-review-voucher/ 2022-12-02T09:55:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/argenx-logo.jpg http://www.pharmajournalist.com/ribon-therapeutics-announces-acquisition-of-pre-clinical-cd38-program-by-boehringer-ingelheim/ 2022-12-02T09:57:55+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/ribon-blue-logo.jpg http://www.pharmajournalist.com/envisagenics-announces-research-collaboration-with-bristol-myers-squibb/ 2022-12-02T09:59:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-fluoxetine-oral-solution-usp/ 2022-12-02T10:00:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/clinigen-adds-pharmacovigilance-capabilities-with-acquisition-of-drug-safety-navigator/ 2022-12-02T10:01:46+00:00 https://pharmajournalist.com/wp-content/uploads/2019/01/Clinigen-Logo.png http://www.pharmajournalist.com/gardp-and-mitsubishi-tanabe-pharma-corporation-announce-partnership-in-search-for-new-antibiotics/ 2022-12-02T10:06:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abcellera-and-rallybio-announce-strategic-alliance-to-discover-develop-and-commercialize-novel-antibody-based-therapeutics-for-rare-diseases/ 2022-12-02T10:08:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/abcellera.jpg http://www.pharmajournalist.com/iecure-raises-65-million-to-advance-in-vivo-gene-editing-programs-for-the-treatment-of-rare-pediatric-liver-diseases/ 2022-12-02T10:10:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/aldeyra-therapeutics-submits-new-drug-application-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/ 2022-12-02T10:31:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kintara-therapeutics-granted-fast-track-designation-from-fda-for-rem-001-for-cutaneous-metastatic-breast-cancer/ 2022-12-02T10:32:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kite-and-daiichi-sankyo-announce-changes-to-yescarta-car-t-cell-therapy-licensing-agreement-in-japan/ 2022-12-08T12:08:34+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/pfizer-and-clear-creek-bio-to-collaborate-on-a-research-program-targeting-sars-cov-2-papain-like-protease/ 2022-12-08T12:09:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/reuters-events-digital-health-event-returns-to-california-to-help-empower-clinicians-engage-patients-and-revive-healthcare/ 2022-12-09T12:23:11+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/Reuters-Events-Logo.png http://www.pharmajournalist.com/vertex-and-entrada-therapeutics-establish-collaboration-to-discover-and-develop-endosomal-escape-vehicle-eev-therapeutics-for-myotonic-dystrophy-type-1-dm1/ 2022-12-09T12:38:05+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/pfizer-and-biontech-submit-application-to-u-s-fda-for-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-bivalent-covid-19-vaccine-in-children-under-5-years/ 2022-12-09T12:39:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-approved-in-canada-for-use-as-a-primary-series-in-adolescents/ 2022-12-09T12:41:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline/ 2022-12-09T12:43:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/touchlight-and-odimma-therapeutics-announce-clinical-material-supply-agreement-to-develop-personalised-cancer-therapy-utilising-doggybone-dna/ 2022-12-09T12:44:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/evaxion-and-expres%c2%b2ion-initiate-research-collaboration-on-a-novel-cytomegalovirus-cmv-vaccine-candidate/ 2022-12-09T12:45:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-u-s-fda-emergency-use-authorization-for-omicron-ba-4-ba-5-adapted-bivalent-covid-19-vaccine-in-children-under-5-years/ 2022-12-09T12:46:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/incyte-and-cms-announce-collaboration-and-license-agreement-for-ruxolitinib-cream-in-greater-china-and-southeast-asia/ 2022-12-09T12:48:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/therapeuticsmd-announces-definitive-agreements-to-license-its-products-to-mayne-pharma/ 2022-12-09T12:49:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/brazilian-regulatory-authority-grants-approval-for-waylivra-for-familial-partial-lipodystrophy/ 2022-12-09T12:52:27+00:00 https://pharmajournalist.com/wp-content/uploads/2020/05/PTC-Therapeutics.jpg http://www.pharmajournalist.com/solid-biosciences-announces-stockholder-approval-of-acquisition-of-aavantibio/ 2022-12-09T12:54:33+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/rocket-pharmaceuticals-completes-acquisition-of-renovacor/ 2022-12-09T12:55:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/rocket-pharmaceuticals-logo.jpg http://www.pharmajournalist.com/immunocore-and-gadeta-announce-agreement-to-develop-first-gamma-delta-%ce%b3%ce%b4-tcr-immtac-for-solid-tumors/ 2022-12-09T12:57:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/09/immunocore.jpg http://www.pharmajournalist.com/solid-biosciences-announces-closing-of-acquisition-of-aavantibio-and-concurrent-75-million-private-placement/ 2022-12-09T12:58:11+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/redhills-aemcolo-granted-fda-qidp-5-year-exclusivity-extension/ 2022-12-09T13:00:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/redhill-biopharma-logo.png http://www.pharmajournalist.com/aarvik-therapeutics-announces-a-global-novel-payload-agreement-with-nj-bio/ 2022-12-09T13:02:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/efruxifermin-granted-fda-breakthrough-therapy-designation-for-nash/ 2022-12-09T13:03:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/vbi-vaccines-announces-health-canada-approval-for-prehevbrio-for-the-prevention-of-hepatitis-b-in-adults/ 2022-12-09T13:05:13+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/VBI-Vaccines-Logo.png http://www.pharmajournalist.com/caris-life-sciences-and-hummingbird-bioscience-enter-into-collaboration-to-advance-clinical-development-of-anti-her3-therapy/ 2022-12-09T13:06:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/ideaya-biosciences-receives-fast-track-designation-for-darovasertib-combination-therapy-with-crizotinib-for-the-treatment-of-metastatic-uveal-melanoma/ 2022-12-09T13:08:01+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/IDEAYA-Biosciences-Logo.jpg http://www.pharmajournalist.com/european-medicines-agency-accepts-marketing-authorisation-application-for-momelotinib-for-the-treatment-of-myelofibrosis/ 2022-12-09T13:09:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/abcellera-and-rallybio-announce-strategic-alliance-to-discover-develop-and-commercialize-novel-antibody-based-therapeutics-for-rare-diseases-2/ 2022-12-09T13:11:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/abcellera.jpg http://www.pharmajournalist.com/registration-is-now-open-for-the-4th-annual-ai-in-drug-discovery-conference/ 2022-12-13T11:55:39+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/AI-in-Drug-Discovery.jpg http://www.pharmajournalist.com/conference-co-chairs-from-merck-astrazeneca-invitation-to-join-3d-cell-culture/ 2022-12-15T12:51:47+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/P-392-Both-Chairmen-Banner.jpg http://www.pharmajournalist.com/wp-content/uploads/2022/12/P-392-Both-Chairmen-Banner.jpg http://www.pharmajournalist.com/exicure-inc-announces-termination-of-abbvie-and-ipsen-collaboration-agreements/ 2022-12-15T12:58:48+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Exicure_Logo.jpg http://www.pharmajournalist.com/ono-enters-into-a-multi-target-rd-collaboration-agreement-with-precisionlife/ 2022-12-15T13:00:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/biosion-announces-research-collaboration-with-immunogen-to-create-novel-antibody-drug-conjugates/ 2022-12-15T13:01:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ucb-and-praxis-precision-medicines-announce-epilepsy-research-collaboration/ 2022-12-15T13:02:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis/ 2022-12-16T09:26:33+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/harrow-enters-into-agreement-to-acquire-exclusive-u-s-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence/ 2022-12-16T09:29:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/merck-signs-mou-with-synplogen-to-accelerate-development-and-manufacturing-of-viral-vector-based-gene-therapy-applications/ 2022-12-16T09:30:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/gsk-and-wave-life-sciences-announce-collaboration-to-drive-discovery-and-development-of-oligonucleotide-therapeutics-focusing-on-novel-genetic-targets/ 2022-12-16T09:33:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/takeda-to-acquire-late-stage-potential-best-in-class-oral-allosteric-tyk2-inhibitor-ndi-034858-from-nimbus-therapeutics/ 2022-12-16T09:34:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/eisai-and-washington-university-school-of-medicine-in-st-louis-enter-into-comprehensive-research-collaboration-agreement-aiming-to-create-new-therapies-for-neurodegenerative-diseases/ 2022-12-16T12:21:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics/ 2022-12-16T12:23:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sobi-receives-approval-from-health-canada-for-empaveli-pegcetacoplan-for-the-treatment-of-certain-patients-with-paroxysmal-nocturnal-hemoglobinuria/ 2022-12-16T12:24:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/sobi.jpg http://www.pharmajournalist.com/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma/ 2022-12-16T12:25:45+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/merck-begins-tender-offer-to-acquire-imago-biosciences/ 2022-12-16T12:27:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/pasithea-therapeutics-announces-comprehensive-settlement-agreement-with-the-camac-group/ 2022-12-16T12:28:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fresenius-kabi-receives-u-s-fda-approval-for-biosimilar-idacio-adalimumab/ 2022-12-16T12:29:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Fresenius-Kabi.jpg http://www.pharmajournalist.com/psyence-and-filament-health-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care/ 2022-12-16T12:31:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gilgamesh-pharmaceuticals-raises-39-million-series-b-to-advance-mental-health-treatments/ 2022-12-16T12:32:45+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/innovent-and-lg-chem-announce-strategic-collaboration-for-tigulixostat-a-novel-non-purine-xanthine-oxidase-inhibitor-for-the-treatment-of-gout-disease/ 2022-12-16T12:34:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/european-commission-approves-spevigo-spesolimab-for-generalized-pustular-psoriasis-flares/ 2022-12-16T12:35:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/hitgen-announces-research-agreement-with-nitrase-therapeutics-focused-on-dna-encoded-library-based-drug-discovery/ 2022-12-16T12:37:12+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Hitgen-Logo.jpg http://www.pharmajournalist.com/berkeley-lights-to-acquire-isoplexis-creating-a-premier-functional-cell-biology-company/ 2022-12-22T16:36:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancer/ 2022-12-22T16:37:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/skye-bioscience-receives-fda-authorization-of-investigational-new-drug-application-for-sbi-100-oe/ 2022-12-22T16:38:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/enhertu-approved-in-the-eu-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer/ 2022-12-22T16:40:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/bioasis-technologies-inc-announces-amendments-to-arrangement-agreement-with-midatech-pharma-plc/ 2022-12-22T16:43:49+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/bioasis-Logo.jpg http://www.pharmajournalist.com/fresenius-kabi-targets-treatment-of-certain-seizures-with-launch-of-generic-lacosamide-injection-usp/ 2022-12-22T16:45:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Fresenius-Kabi.jpg http://www.pharmajournalist.com/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology/ 2022-12-22T16:46:05+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/capsida-biotherapeutics-announces-strategic-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-develop-non-invasive-gene-therapies-for-cns-diseases/ 2023-01-06T09:43:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/belharra-therapeutics-announces-broad-collaboration-with-genentech-to-discover-and-develop-novel-medicines-across-multiple-therapeutic-areas/ 2023-01-06T09:44:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/maxcyte-signs-strategic-platform-license-with-catamaran-bio-to-support-its-car-nk-cell-therapy-programs/ 2023-01-06T09:49:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/transcenta-received-ind-clearance-from-nmpa-for-its-first-in-class-gremlin1-targeting-antibody-tst003-for-the-treatment-of-solid-tumors/ 2023-01-06T09:50:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies/ 2023-01-06T09:52:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/alpha-healthcare-acquisition-corp-iii-announces-merger-with-carmell-therapeutics-a-phase-2-stage-biotechnology-platform-company-developing-allogeneic-plasma-based-biomaterials-for-bone-and-soft-tiss/ 2023-01-06T09:54:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/alligator-bioscience-and-orion-corporation-announce-the-initiation-of-the-second-program-of-their-immuno-oncology-research-collaboration-and-license-agreement/ 2023-01-06T09:56:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/alligator-bioscience-logo.jpg http://www.pharmajournalist.com/alteogen-enters-into-an-exclusive-license-agreement-to-develop-and-commercialize-biosimilar-products-enabled-by-alteogens-hybrozyme-technology/ 2023-01-06T09:58:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/mayflower-bioventures-launches-its-first-spin-out-primera-therapeutics-in-strategic-collaboration-with-cellectis-to-develop-a-gene-editing-platform-to-treat-mitochondrial-diseases/ 2023-01-06T10:00:19+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Cellectis-Logo.png http://www.pharmajournalist.com/imfinzi-plus-imjudo-approved-in-japan-for-advanced-liver-and-non-small-cell-lung-cancers-and-imfinzi-approved-for-unresectable-biliary-tract-and-liver-cancers/ 2023-01-06T10:03:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/gilead-to-acquire-all-remaining-rights-to-potential-first-in-class-immunotherapy-gs-1811-from-jounce-therapeutics/ 2023-01-06T10:05:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/orbit-discovery-and-sanegenebio-collaborate-to-identify-targeting-peptides-for-rnai-drugs/ 2023-01-06T10:07:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/simnova-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-circular-rna-technology-in-china/ 2023-01-06T10:09:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi-multi-specific-t-cell-engagers/ 2023-01-06T10:10:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/moderna-to-acquire-oriciro-genomics/ 2023-01-06T10:12:30+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/moderna-and-cytomx-announce-strategic-research-collaboration-for-mrna-based-conditionally-activated-therapeutics/ 2023-01-06T10:21:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/amerisourcebergen-completes-acquisition-of-pharmalex/ 2023-01-06T10:23:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/10/Amerisource.jpg http://www.pharmajournalist.com/mission-bio-and-abiosciences-partner-to-co-develop-bioinformatics-for-clinical-research-applications-in-china/ 2023-01-06T10:25:49+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/MissionBio_Logo.jpg http://www.pharmajournalist.com/opus-genetics-announces-acquisition-of-the-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/ 2023-01-06T10:28:39+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/logo-opus_genetics.png http://www.pharmajournalist.com/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/ 2023-01-06T10:29:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/kala-Pharmaceuticals-Logo.png http://www.pharmajournalist.com/ablaze-pharmaceuticals-and-yonghe-pharma-initiate-development-and-manufacturing-services-agreement-for-targeted-radiopharmaceutical-therapies/ 2023-01-06T10:31:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/hikma-and-junshi-biosciences-sign-exclusive-licensing-agreement-for-cancer-treatment-drug-toripalimab-for-the-middle-east-and-north-africa-region/ 2023-01-06T10:32:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/01/hikma-logo.jpg http://www.pharmajournalist.com/merck-announces-collaboration-with-mersana-therapeutics-to-develop-novel-immunostimulatory-antibody-drug-conjugates/ 2023-01-06T10:33:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-cincor-pharma-to-strengthen-cardiorenal-pipeline/ 2023-01-13T10:16:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/enhertu-approved-by-health-canada-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer/ 2023-01-13T10:18:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/avillion-announces-us-approval-of-astrazenecas-airsupra-pt027-as-new-rescue-treatment-for-asthma/ 2023-01-13T10:19:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/takedas-exkivity-mobocertinib-receives-approval-from-the-nmpa-of-china-becoming-the-first-and-only-therapy-available-for-patients-with-egfr-exon20-insertion-nsclc/ 2023-01-13T10:21:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/biontech-to-acquire-instadeep-to-strengthen-pioneering-position-in-the-field-of-ai-powered-drug-discovery-design-and-development/ 2023-01-13T10:22:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa/ 2023-01-13T10:23:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-and-anima-biotech-announce-collaboration-for-the-discovery-and-development-of-mrna-biology-modulators-against-oncology-and-immunology-targets/ 2023-01-13T10:25:04+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/abbvie-logo.jpg http://www.pharmajournalist.com/solid-biosciences-and-phlox-therapeutics-announce-strategic-research-collaboration-focused-on-accelerating-the-development-of-new-therapies-for-rare-cardiac-diseases/ 2023-01-13T10:27:44+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/recode-therapeutics-announces-strategic-collaboration-with-askbio-to-explore-single-vector-gene-editing-platform/ 2023-01-13T10:52:19+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies/ 2023-01-13T10:53:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets/ 2023-01-13T10:54:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-pathway-for-the-treatment-of-alzheimers-disease/ 2023-01-13T10:56:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/adcendo-aps-announces-license-agreement-with-duality-biologics-on-next-generation-adc-platform/ 2023-01-13T10:57:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children-up-to-age-24-months/ 2023-01-13T10:59:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/synaffix-enters-license-agreement-with-amgen-to-build-next-generation-adcs/ 2023-01-13T11:00:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/preveceutical-enters-into-license-option-agreement-with-endosane-pharmaceuticals/ 2023-01-13T11:02:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/catalent-and-ethicann-sign-development-and-license-agreement-for-new-fast-dissolve-cannabinoid-based-treatments/ 2023-01-13T11:06:50+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Catalent-Logo.png http://www.pharmajournalist.com/merck-completes-tender-offer-to-acquire-imago-biosciences/ 2023-01-13T11:07:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/syneos-health-announces-partnership-with-fosun-pharma-usa-to-launch-serplulimab/ 2023-01-13T11:09:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Syneos-Health-Logo.png http://www.pharmajournalist.com/alora-pharmaceuticals-celebrates-acquisition-of-monarch-manufacturing-facility/ 2023-01-13T11:11:43+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/Alora_Logo.jpg http://www.pharmajournalist.com/janone-inc-completes-acquisition-of-soin-therapeutics/ 2023-01-13T11:13:50+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/selecta-biosciences-and-astellas-announce-exclusive-licensing-and-development-agreement-for-xork-igg-protease/ 2023-01-13T11:15:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/askbio-announces-strategic-collaboration-with-recode-therapeutics-to-explore-single-vector-gene-editing-platform/ 2023-01-13T11:16:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/AskBio-Logo.jpe http://www.pharmajournalist.com/servier-and-aqemia-extend-collaboration-on-undruggable-target-in-immuno-oncology/ 2023-01-13T11:17:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Servier-CDMO.png http://www.pharmajournalist.com/daiichi-sankyo-submits-application-for-marketing-approval-of-mrna-covid-19-vaccine-ds-5670-in-japan/ 2023-01-13T11:28:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/myrtelle-and-raaven-therapeutics-to-develop-novel-gene-therapy-vectors/ 2023-01-13T11:32:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/cancer-neoantigen-vaccines-a-1-day-digital-conference-by-informa-connect/ 2023-01-16T18:50:44+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/Cancer-Neoantigen-Vaccines.jpg http://www.pharmajournalist.com/bird-rock-bio-files-ind-application-for-phase-2-study-of-nimacimab-for-treatment-of-renal-diseases/ 2023-01-17T13:59:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/evoq-therapeutics-and-amgen-expanding-collaboration/ 2023-01-19T09:21:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/novavax-nuvaxovid-covid-19-vaccine-approved-in-south-korea-as-an-adult-booster/ 2023-01-19T09:22:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/merck-selects-perceiv-ai-for-inaugural-digital-sciences-studio-cohort/ 2023-01-19T09:23:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/brukinsa-zanubrutinib-receives-marketing-authorization-for-chronic-lymphocytic-leukemia-cll-and-marginal-zone-lymphoma-mzl-in-great-britain-by-mhra/ 2023-01-20T11:01:56+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/sun-pharma-to-acquire-concert-pharmaceuticals-advancing-the-potential-treatment-of-alopecia-areata/ 2023-01-20T11:04:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/SunPharma.jpg http://www.pharmajournalist.com/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1020-for-the-treatment-of-facioscapulohumeral-muscular-dystrophy/ 2023-01-20T11:06:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/affamed-therapeutics-to-commercialize-galcanezumab-for-migraine-prevention-in-mainland-china/ 2023-01-20T11:08:51+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/AffaMed-Logo.png http://www.pharmajournalist.com/orphagen-pharmaceuticals-receives-rare-pediatric-disease-designation-from-fda-for-or-449-for-the-treatment-of-pediatric-adrenocortical-carcinoma/ 2023-01-20T11:10:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/aprinoia-therapeutics-and-ross-acquisition-corp-ii-announce-business-combination-agreement-to-create-publicly-listed-company-focused-on-neurodegenerative-diseases/ 2023-01-20T11:11:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/amylyx-pharmaceuticals-announces-exclusive-amx0035-distribution-agreement-with-israel-based-neopharm/ 2023-01-20T11:22:13+00:00 https://pharmajournalist.com/wp-content/uploads/2019/12/Amylyx-Logo.jpg http://www.pharmajournalist.com/carsgen-therapeutics-and-huadong-medicine-announce-collaboration-agreement-for-zevorcabtagene-autoleucel-in-mainland-china/ 2023-01-20T11:23:26+00:00 https://pharmajournalist.com/wp-content/uploads/2019/11/Carsgen-Therapeutics-Logo.jpg http://www.pharmajournalist.com/fda-approves-luye-pharmas-rykindo-for-the-treatment-of-schizophrenia-and-bipolar-1-disorder/ 2023-01-20T11:25:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ono-enters-an-option-and-research-collaboration-agreement-with-monash-university-to-discover-anti-gpcr-antibodies-in-the-autoimmune-and-inflammatory-diseases/ 2023-01-20T11:31:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen/ 2023-01-20T11:33:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/roche-announces-the-european-commission-approval-of-xofluza-for-the-treatment-and-prevention-of-influenza-in-children-aged-one-year-and-above/ 2023-01-20T11:35:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/sabin-vaccine-institute-receives-35-million-from-barda-with-potential-of-up-to-214-million-for-ebola-sudan-and-marburg-vaccines/ 2023-01-20T11:37:08+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-launches-new-collaboration-with-oerth-bio-to-further-advance-innovations-in-crop-protection/ 2023-01-20T18:29:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/advaxis-and-ayala-pharmaceuticals-complete-merger/ 2023-01-20T11:40:02+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/phanes-therapeutics-anti-claudin-18-2-antibody-patent-granted-in-the-us/ 2023-01-20T11:42:53+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/Phanes-Therapeutics-logo.png http://www.pharmajournalist.com/evaxion-receives-fda-fast-track-designation-for-personalized-cancer-immunotherapy/ 2023-01-20T11:44:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/forge-biologics-receives-priority-medicines-prime-designation-from-the-european-medicines-agency-ema-for-novel-gene-therapy-fbx-101-for-the-treatment-of-patients-with-krabbe-disease/ 2023-01-20T11:46:12+00:00 https://pharmajournalist.com/wp-content/uploads/2021/07/Forge_Biologics.jpg http://www.pharmajournalist.com/china-nmpa-approves-bio-thera-solutions-bat1806-a-biosimilar-to-actemra-tocilizumab/ 2023-01-20T11:48:37+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/Bio-Thera-Logo.png http://www.pharmajournalist.com/cancer-neoantigen-vaccines-a-1-day-digital-conference-by-informa-connect-2/ 2023-01-24T10:54:22+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/Cancer-Neoantigen-Vaccines.jpg http://www.pharmajournalist.com/sandoz-announces-agreement-to-acquire-leading-antifungal-agent-mycamine-from-astellas-reinforcing-hospital-offering-and-leading-anti-infectives-portfolio/ 2023-01-26T11:45:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/takeda-to-acquire-exclusive-worldwide-ex-china-license-of-hutchmeds-fruquintinib-a-highly-selective-oral-vegfr1-2-3-tyrosine-kinase-inhibitor/ 2023-01-26T11:47:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kidney-disease/ 2023-01-26T11:48:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/roche-launches-covid-19-pcr-test-to-detect-the-fast-spreading-xbb-1-5-omicron-sub-variant/ 2023-01-27T09:59:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/evotec-announces-agreement-with-janssen-to-develop-immune-based-therapies/ 2023-01-27T10:01:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/cytomx-therapeutics-announces-milestone-achievement-in-probody-t-cell-engaging-bispecific-tcb-collaboration-with-astellas/ 2023-01-27T10:02:30+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Cytomx-Logo.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-partners-with-astrazeneca-to-develop-solid-tissue-and-blood-based-companion-diagnostic-test-for-tagrisso/ 2023-01-27T10:04:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/lupin-launches-lyfe-its-digital-therapeutic-solution-for-holistic-heart-care/ 2023-01-27T10:05:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/lupin-pharma.jpg http://www.pharmajournalist.com/blueprint-medicines-announces-fda-acceptance-of-supplemental-new-drug-application-for-ayvakit-avapritinib-for-the-treatment-of-indolent-systemic-mastocytosis/ 2023-01-27T10:06:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tscan-therapeutics-announces-fda-clearance-of-three-investigational-new-drug-applications-for-the-treatment-of-solid-tumors/ 2023-01-27T10:33:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/poxel-receives-orphan-drug-designation-from-the-european-commission-for-pxl770-and-pxl065-for-treatment-of-adrenoleukodystrophy/ 2023-01-27T10:35:31+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/poxel-logo.png http://www.pharmajournalist.com/alvotech-and-bioventure-announce-approval-of-avt02-adalimumab-as-simlandi-in-saudi-arabia/ 2023-01-27T10:36:42+00:00 https://pharmajournalist.com/wp-content/uploads/2019/08/alvotech-facility.jpg http://www.pharmajournalist.com/biocryst-selects-swixx-biopharma-as-commercial-partner-for-orladeyo-berotralstat-in-central-and-eastern-europe/ 2023-01-27T10:38:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/biocryst-pharma.jpg http://www.pharmajournalist.com/disc-medicine-announces-exclusive-licensing-agreement-with-mabwell-therapeutics-for-novel-anti-tmprss6-monoclonal-antibodies-to-modulate-iron-homeostasis/ 2023-01-27T10:40:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-bioarctic/ 2023-01-27T10:43:01+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/EISAI.jpg http://www.pharmajournalist.com/rewind-therapeutics-raises-additional-funding-and-adds-sunstone-life-science-ventures-a-s-as-new-investor/ 2023-01-27T10:44:03+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/hyloris-announces-commercial-partnership-for-maxigesic-iv-in-9-european-countries/ 2023-01-27T10:45:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/genexine-receives-fast-track-designation-from-korean-health-authority-mfds-for-its-promising-dna-vaccine-for-advanced-cervical-cancer/ 2023-01-27T10:48:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/evaxion-receives-fda-fast-track-designation-for-personalized-cancer-immunotherapy-2/ 2023-01-27T10:49:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/exegenesis-bio-announces-fda-clearance-of-investigational-new-drug-ind-application-for-exg102-031-a-novel-gene-therapy-for-the-treatment-of-neovascular-age-related-macular-degeneration-namd/ 2023-01-27T10:50:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/cidara-therapeutics-and-wuxi-xdc-expand-collaboration-for-ind-enabling-cmc-development-to-advance-cidaras-cd73-oncology-dfc-program/ 2023-02-02T11:29:54+00:00 https://pharmajournalist.com/wp-content/uploads/2019/09/CIDARA-THERAPEUTICS.png http://www.pharmajournalist.com/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/ 2023-02-02T11:31:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/ellipses-pharma-announces-fda-approval-of-ind-application-for-ep0042-for-patients-with-acute-myeloid-leukaemia/ 2023-02-02T11:32:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/karuna-therapeutics-announces-exclusive-global-license-agreement-for-goldfinch-bios-investigational-trpc4-5-product-candidates/ 2023-02-03T09:51:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/Karuna_Logo.jpg http://www.pharmajournalist.com/md-anderson-and-federation-bio-announce-collaboration-to-develop-novel-microbiome-treatment-for-patients-with-immunotherapy-resistant-cancers/ 2023-02-03T09:53:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/uniqure-and-apic-bio-enter-into-global-licensing-agreement-for-apb-102-a-clinical-stage-gene-therapy-for-patients-with-als-caused-by-mutations-in-sod1/ 2023-02-03T09:55:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/uniqure.jpg http://www.pharmajournalist.com/daewoong-enters-exclusive-licensing-agreement-with-cs-pharmaceuticals-for-bersiporocin-in-idiopathic-pulmonary-fibrosis-in-the-greater-china-region/ 2023-02-03T09:57:08+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/Daewoong___CS_Pharmaceuticals.jpg https://pharmajournalist.com/wp-content/uploads/2023/02/Daewoong___CS_Pharmaceuticals.jpg http://www.pharmajournalist.com/sandoz-receives-positive-chmp-opinion-for-citrate-free-high-concentration-formulation-of-adalimumab-biosimilar/ 2023-02-03T09:58:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis/ 2023-02-03T10:00:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/pliant-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-pln-101095-a-novel-integrin-inhibitor-for-the-treatment-of-solid-tumors/ 2023-02-03T10:03:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/4d-molecular-therapeutics-announces-fda-clearance-of-ind-application-for-4d-150-genetic-medicine-for-the-treatment-of-diabetic-macular-edema/ 2023-02-03T10:04:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/tonix-pharmaceuticals-announces-acquisition-of-preclinical-infectious-disease-portfolio-from-healion-bio-inc/ 2023-02-03T10:05:36+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/tonix-pharmaceuticals.png http://www.pharmajournalist.com/pharmather-holdings-announces-fda-grant-of-orphan-drug-designation-to-ketarx-ketamine-for-the-treatment-of-rett-syndrome/ 2023-02-03T10:07:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/benlysta-granted-orphan-drug-designation-by-us-fda-for-the-potential-treatment-of-systemic-sclerosis/ 2023-02-03T10:09:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/cybin-announces-approval-of-first-in-human-dosing-of-its-proprietary-dmt-molecule-cyb004/ 2023-02-03T10:11:52+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/Cybin_Logo.png http://www.pharmajournalist.com/hillstream-biopharma-signs-an-exclusive-option-agreement-to-advance-next-generation-anti-muc1-c-agents-for-drug-resistant-cancers/ 2023-02-03T10:13:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ascletis-announces-u-s-fda-approval-of-conducting-a-phase-iia-clinical-trial-for-asc10-to-treat-respiratory-syncytial-virus-infection/ 2023-02-03T10:14:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ascletis-logo.jpg http://www.pharmajournalist.com/xeris-biopharma-announces-fda-grants-orphan-drug-exclusivity-for-recorlev/ 2023-02-03T10:17:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Xeris-Logo.jpg http://www.pharmajournalist.com/charles-river-laboratories-acquires-samdi-tech/ 2023-02-03T10:18:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/charles-river-lab.png http://www.pharmajournalist.com/sun-pharma-acquires-disperzyme-and-phlogam-brands-to-strengthen-its-anti-inflammatory-portfolio/ 2023-02-03T10:20:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/SunPharma.jpg http://www.pharmajournalist.com/purple-biotech-expands-pipeline-of-first-in-class-therapeutics-with-acquisition-of-immunorizon-and-its-portfolio-of-tri-specific-antibodies-for-the-treatment-of-cancer/ 2023-02-03T10:22:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-stargardt-disease/ 2023-02-03T10:24:01+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/Nanoscope_Therapeutics_Logo.jpg http://www.pharmajournalist.com/rewind-therapeutics-raises-additional-funding-and-adds-sunstone-life-science-ventures-a-s-as-new-investor-2/ 2023-02-03T10:25:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/balance-digital-virtual-and-in-person-treatment-to-integrate-your-behavioral-healthcare/ 2023-02-08T09:27:15+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/Calm-Webinar-1200-%C3%97-627-banner-1.png http://www.pharmajournalist.com/wp-content/uploads/2023/02/Calm-Webinar-1200-%C3%97-627-banner-1.png http://www.pharmajournalist.com/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/ 2023-02-10T12:31:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/vial-partners-with-egnyte-to-integrate-life-sciences-etmf-solution-into-their-clinical-trial-platform/ 2023-02-10T12:32:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/revir-therapeutics-and-asieris-pharmaceuticals-enter-into-agreement-to-discover-oncology-therapeutics-based-on-revirs-comprehensive-approach-to-rna-targeted-technologies/ 2023-02-10T12:33:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/eylea-aflibercept-injection-approved-as-the-first-pharmacologic-treatment-for-preterm-infants-with-retinopathy-of-prematurity-rop-by-the-fda/ 2023-02-10T12:34:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/genenta-science-and-agc-biologics-enter-development-and-manufacturing-service-agreement/ 2023-02-10T12:36:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/aldeyra-therapeutics-announces-fda-acceptance-of-new-drug-application-for-reproxalap-for-the-treatment-of-dry-eye-disease/ 2023-02-10T12:37:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure/ 2023-02-10T12:39:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/tavneos-avacopan-approved-in-australia-for-the-treatment-of-anca-associated-vasculitis/ 2023-02-10T12:41:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/sandoz-biologics-license-application-for-proposed-biosimilar-denosumab-accepted-by-us-fda/ 2023-02-10T12:43:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/feinstein-institutes-researcher-discovers-potential-therapeutic-target-for-lethal-sepsis/ 2023-02-10T12:46:40+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/Wang_News_2023.jpg https://pharmajournalist.com/wp-content/uploads/2023/02/Wang_News_2023.jpg http://www.pharmajournalist.com/fda-approves-trodelvy-in-pre-treated-hr-her2-metastatic-breast-cancer/ 2023-02-10T12:48:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/evotec-and-related-sciences-expand-integrated-drug-discovery-and-development-partnership/ 2023-02-10T12:50:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/roche-expands-collaboration-with-janssen-to-advance-personalised-healthcare-through-companion-diagnostics/ 2023-02-10T12:51:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/intelgenx-announces-research-collaboration-with-renowned-neurologist-to-evaluate-montelukast-versafilm-for-the-treatment-of-parkinsons-disease/ 2023-02-10T12:53:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/creative-medical-technology-holdings-announces-irb-approval-for-fda-cleared-phase-1-2-clinical-trial-of-novel-cell-therapy-for-the-treatment-of-type-1-diabetes/ 2023-02-10T12:54:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-for-rexlemestrocel-l-in-chronic-low-back-pain/ 2023-02-10T12:55:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/mesoblast-logo.png http://www.pharmajournalist.com/west-expands-corning-collaboration-and-launches-first-product/ 2023-02-10T12:58:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/West-Pharmaceutical.png http://www.pharmajournalist.com/kiora-pharmaceuticals-receives-investigational-new-drug-approval-for-phase-2-study-of-kio-101-for-treatment-of-ocular-presentation-of-autoimmune-diseases/ 2023-02-10T13:00:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/drug.jpg http://www.pharmajournalist.com/syneos-health-and-haystack-health-partner-to-accelerate-clinical-trials-with-ai/ 2023-02-10T13:01:26+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Syneos-Health-Logo.png http://www.pharmajournalist.com/atreca-and-xencor-to-develop-t-cell-engaging-bispecific-antibody-directed-against-novel-solid-tumor-target/ 2023-02-10T13:03:00+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Xencor_Logo.png http://www.pharmajournalist.com/ultima-genomics-announces-collaboration-with-10x-genomics-to-enable-seamless-integration-of-chromium-single-cell-applications-on-ultima-sequencers/ 2023-02-10T13:04:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sensei-biotherapeutics-signs-cooperative-research-and-development-agreement-crada-with-the-national-cancer-institute-nci-to-expand-development-plan-for-sns-101-a-conditionally-active-vista-blocki/ 2023-02-10T13:05:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/biogen-and-sage-therapeutics-announce-fda-accepts-filing-of-new-drug-application-and-grants-priority-review-of-zuranolone-in-the-treatment-of-major-depressive-disorder-and-postpartum-depression/ 2023-02-10T13:07:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/aqilion-announces-pre-clinical-licensing-and-strategic-research-collaboration-agreement-with-merck/ 2023-02-17T08:36:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/first-gene-therapy-for-hemophilia-b-csls-hemgenix-approved-by-the-european-commission/ 2023-02-21T09:26:01+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/CSL-Logo.png http://www.pharmajournalist.com/gxp-systems-validation-not-a-one-time-occurrence/ 2023-02-21T09:26:32+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/VamshiMannem2022.jpg https://pharmajournalist.com/wp-content/uploads/2023/01/InitialValidation.png https://pharmajournalist.com/wp-content/uploads/2023/01/PeriodicReviewandRe-Validation.png https://pharmajournalist.com/wp-content/uploads/2023/01/VamshiMannem2022.jpg http://www.pharmajournalist.com/clover-enters-into-exclusive-agreement-to-commercialize-quadrivalent-seasonal-influenza-vaccine-in-mainland-china/ 2023-02-21T09:28:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-accepts-valnevas-chikungunya-vaccine-license-application-for-priority-review/ 2023-02-21T09:29:54+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/fda-accepts-for-priority-review-the-supplemental-new-drug-application-for-mercks-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-kidney-transplant-recipients-at-high-risk/ 2023-02-21T09:31:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/teva-announces-fda-approval-of-austedo-xr-deutetrabenazine-extended-release-tablets-a-new-once-daily-formulation-of-austedo-deutetrabenazine-tablets/ 2023-02-21T09:32:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/TEVA-Pharma.jpg http://www.pharmajournalist.com/keymed-and-lepu-biopharma-have-announced-a-global-exclusive-licensing-agreement-with-astrazeneca-for-cmg901/ 2023-02-24T10:36:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/the-eu-has-approved-the-tablet-formulation-of-calquence-for-patients-suffering-from-chronic-lymphocytic-leukaemia/ 2023-02-24T10:38:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/a-strategic-partnership-for-gmp-plasmid-dna-manufacturing-for-an-mrna-covid-19-vaccine-candidate-has-been-announced-by-genscript-probio-and-rvac-medicines/ 2023-02-24T10:41:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/GenScript.jpg http://www.pharmajournalist.com/fda-has-granted-fast-track-designation-to-biohavens-taldefgrobep-alfa-for-the-treatment-of-spinal-muscular-atrophy/ 2023-02-24T10:43:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/uk-grants-full-marketing-authorization-to-karyopharm-and-menarini-groups-nexpovio-for-multiple-myeloma-treatment/ 2023-02-24T10:46:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/karyopharma-logo.png http://www.pharmajournalist.com/moderna-and-life-edit-therapeutics-form-strategic-partnership-to-advance-in-vivo-gene-editing-therapies/ 2023-02-24T10:49:40+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/pozelimab-c5-antibody-bla-for-treatment-of-children-and-adults-with-ultra-rare-chaple-disease-accepted-for-fda-priority-review/ 2023-02-24T10:51:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/syfovre-pegcetacoplan-injection-approved-by-fda-as-the-first-and-only-treatment-for-leading-cause-of-blindness-geographic-atrophy-ga/ 2023-02-24T10:55:05+00:00 https://pharmajournalist.com/wp-content/uploads/2019/03/Apellis-Pharma-Logo.jpg http://www.pharmajournalist.com/m2gen-and-zephyr-ai-collaborate-to-advance-cancer-treatment-and-cure-discovery-for-patients/ 2023-02-24T10:57:41+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/capricor-therapeutics-and-nippon-shinyaku-form-partnership-for-cap-1002-distribution-in-japan-treating-duchenne-muscular-dystrophy/ 2023-02-24T11:00:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/capricor-therapeutics-logo.jpg http://www.pharmajournalist.com/eterna-therapeutics-and-lineage-cell-therapeutics-partner-to-develop-hypoimmune-pluripotent-cell-lines-for-multiple-neurology-indications/ 2023-02-24T11:04:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/pfizers-rsv-maternal-vaccine-candidate-bla-accepted-by-fda-for-priority-review/ 2023-02-24T11:07:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/fda-accepts-alnylams-supplemental-nda-for-onpattro-patisiran-to-treat-cardiomyopathy-in-attr-amyloidosis/ 2023-02-24T11:09:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/alnylam-pharmaceuticals_logo.jpg http://www.pharmajournalist.com/vaxcytes-vax-24-ind-cleared-by-fda-for-prevention-of-invasive-pneumococcal-disease-in-infants/ 2023-02-24T11:11:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/beckley-psytechs-bpl-003-a-synthetic-formulation-of-5-meo-dmt-mebufotenin-granted-fda-investigational-new-drug-ind-approval-for-phase-iib-clinical-trial/ 2023-02-24T11:13:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/xspray-pharma-and-eversana-team-up-for-u-s-launch-and-commercialization-of-dasynoc-xs004-a-promising-therapy-for-cml-and-all/ 2023-02-24T11:18:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sage-therapeutics-sage-718-granted-orphan-drug-designation-by-european-medicines-agency-for-huntingtons-disease-treatment/ 2023-02-24T11:20:50+00:00 https://pharmajournalist.com/wp-content/uploads/2023/02/Sage_logo.jpg http://www.pharmajournalist.com/oragenics-and-inspirevax-team-up-for-intranasal-covid-vaccine-candidate-with-global-license-agreement/ 2023-03-02T09:36:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tevard-biosciences-and-vertex-partner-to-create-breakthrough-trna-based-treatments-for-duchenne-muscular-dystrophy/ 2023-03-02T09:39:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/12/Tevard-Biosciences-Logo.jpg http://www.pharmajournalist.com/sunshine-biopharma-signs-exclusive-worldwide-license-with-university-of-arizona-for-plpro-based-covid-19-treatment/ 2023-03-02T09:41:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/confo-therapeutics-announces-global-licensing-agreement-with-lilly-for-peripheral-pain-candidate-cftx-1554/ 2023-03-03T11:08:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Confo-Therapeutics-logo.png http://www.pharmajournalist.com/immunogen-announces-a-global-multi-target-license-and-option-agreement-with-vertex-for-the-use-of-immunogens-adc-technology-in-the-development-of-novel-targeted-conditioning-agents/ 2023-03-03T11:10:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Immunogen-Logo.png http://www.pharmajournalist.com/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalgia-rheumatica/ 2023-03-03T11:13:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/reata-pharmaceuticals-announces-fda-approval-of-skyclarys-omaveloxolone-the-first-and-only-drug-indicated-for-patients-with-friedreichs-ataxia/ 2023-03-03T11:15:22+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/Reata-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/intellia-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ntla-2002-an-in-vivo-crispr-based-investigational-therapy-for-the-treatment-of-hereditary-angioedema-h/ 2023-03-03T11:17:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio/ 2023-03-03T11:19:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/the-bristol-myers-squibb-janssen-collaboration-launches-pivotal-phase-3-librexia-clinical-trial-program-evaluating-milvexian-an-investigational-oral-factor-xia-inhibitor/ 2023-03-03T11:23:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/chugai-and-biofourmis-enter-into-new-partnership-focused-on-data-driven-virtual-care-for-endometriosis-related-pain/ 2023-03-03T11:25:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer/ 2023-03-03T11:27:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/bionxt-signs-clinical-study-agreement-and-commences-manufacture-of-clinical-samples-for-study-of-transdermal-rotigotine-patch-for-parkinsons-disease/ 2023-03-03T11:31:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/ocugen-inc-announces-submission-of-investigational-new-drug-application-with-u-s-fda-to-initiate-a-phase-1-clinical-trial-evaluating-ocu200-for-the-treatment-of-diabetic-macular-edema/ 2023-03-03T11:34:22+00:00 https://pharmajournalist.com/wp-content/uploads/2019/10/Ocugen_Logo.jpg http://www.pharmajournalist.com/rhythm-pharmaceuticals-announces-acquisition-of-xinvento-b-v-and-portfolio-of-investigational-therapeutics/ 2023-03-03T11:37:02+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/Rhythm-Logo.jpg http://www.pharmajournalist.com/lantern-pharma-and-ttc-oncology-establish-ai-collaboration-to-expand-the-clinical-development-of-drug-candidate-ttc-352/ 2023-03-03T11:38:31+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/Lantern-Pharma-Logo.png http://www.pharmajournalist.com/azenta-launches-cryo-store-pico-a-novel-automated-cryogenic-storage-system-designed-for-clinical-and-laboratory-applications/ 2023-03-03T11:41:51+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/Azenta_Logo.jpg http://www.pharmajournalist.com/singleron-biotechnologies-and-macrogen-europe-announce-a-strategic-alliance/ 2023-03-03T11:50:24+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease/ 2023-03-03T11:52:14+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/abbvie-logo.jpg http://www.pharmajournalist.com/avenue-therapeutics-enters-into-a-transformational-license-agreement-with-annji-pharmaceutical-to-develop-and-commercialize-aj201-a-first-in-class-clinical-asset-for-the-treatment-of-spinal-and-bulba/ 2023-03-03T11:53:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/nexus-pharmaceuticals-inc-receives-fda-approval-for-emerphed-ephedrine-sulfate-injection-pre-filled-syringe/ 2023-03-03T11:56:08+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/EMERPHED.jpg https://pharmajournalist.com/wp-content/uploads/2023/03/EMERPHED.jpg http://www.pharmajournalist.com/tempus-announces-new-strategic-collaboration-with-pfizer-to-advance-oncology-therapeutic-development/ 2023-03-03T12:09:39+00:00 https://pharmajournalist.com/wp-content/uploads/2022/10/logo_tempus.jpg http://www.pharmajournalist.com/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adults-and-adolescents-accepted-for-fda-review/ 2023-03-10T09:15:36+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/sun-pharma-completes-acquisition-of-concert-pharmaceuticals/ 2023-03-10T09:17:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/SunPharma.jpg http://www.pharmajournalist.com/fda-accepts-eisai-and-biogen-supplemental-biologics-licence-application/ 2023-03-10T09:18:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-udenyca-autoinjector/ 2023-03-10T09:20:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sandoz-signs-memorandum-of-understanding-to-build-new-biologics-production-plant-in-slovenia-to-support-increasing-global-demand-for-biosimilar-medicines/ 2023-03-10T11:10:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/cancer-research-uk-signs-multi-project-collaboration-with-ucb-to-advance-oncology-antibody-candidates/ 2023-03-10T11:11:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/opko-healths-modex-therapeutics-enters-into-exclusive-worldwide-license-and-collaboration-agreement-with-merck-to-develop-epstein-barr-virus-vaccine-candidate/ 2023-03-10T11:12:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tessa-therapeutics-enters-into-cooperative-research-and-development-agreement-crada-with-the-u-s-national-cancer-institute/ 2023-03-10T11:14:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/shorla-oncology-announces-u-s-fda-approval-of-nelarabine-injection-for-the-treatment-of-t-cell-leukemia/ 2023-03-10T11:15:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/alnylam-pharmaceuticals-and-medison-pharma-announce-the-expansion-of-their-collaboration-to-a-multi-regional-partnership-to-commercialize-rnai-therapeutics/ 2023-03-10T11:19:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/alnylam-pharmaceuticals_logo.jpg http://www.pharmajournalist.com/vertex-announces-fda-clearance-of-investigational-new-drug-application-for-vx-264-a-novel-encapsulated-cell-therapy-for-the-treatment-of-type-1-diabetes/ 2023-03-10T11:21:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/pfizer-invests-43-billion-to-battle-cancer/ 2023-03-15T10:44:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-u-s-emergency-use-authorization-of-omicron-ba-4-ba-5-adapted-bivalent-covid-19-booster-in-children-under-5-years/ 2023-03-15T10:46:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sanofi-to-acquire-provention-bio-adding-to-portfolio-tzield-the-first-disease-modifying-treatment-for-the-delay-of-stage-3-type-1-diabetes-t1d/ 2023-03-15T10:47:43+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/cytovance-biologics-and-phenotypeca-collaborate-to-enhance-saccharomyces-cerevisiae-strain-development-for-microbial-biomanufacturing/ 2023-03-15T10:48:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Cytovance-Biologics-logo.jpg http://www.pharmajournalist.com/exclusive-attendee-list-released-for-the-inaugural-mrna-process-development-manufacturing-summit-europe/ 2023-03-16T10:15:45+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/Pharma-J-Press-Release.png http://www.pharmajournalist.com/wp-content/uploads/2023/03/Pharma-J-Press-Release.png http://www.pharmajournalist.com/novartis-tafinlar-mekinist-approved-by-fda-for-pediatric-patients-with-braf-v600e-low-grade-glioma-the-most-common-pediatric-brain-cancer/ 2023-03-17T10:47:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/aitia-and-ucb-announce-strategic-drug-discovery-collaboration-in-huntingtons-disease/ 2023-03-17T11:42:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/acelrx-pharmaceuticals-announces-divestment-of-dsuvia-to-alora-pharmaceuticals/ 2023-03-17T11:47:34+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/AcelRx-Pharma-logo.jpg http://www.pharmajournalist.com/cingulate-and-indegene-announce-joint-commercialization-agreement-for-lead-adhd-candidate-ctx-1301/ 2023-03-17T11:51:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/immunoprecise-antibodies-subsidiary-talem-therapeutics-announces-a-multi-target-ai-driven-antibody-discovery-collaboration-with-libera-bio/ 2023-03-17T11:53:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/evotec-announces-progress-in-strategic-protein-degradation-partnership-with-bristol-myers-squibb/ 2023-03-17T11:56:07+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/ipsen-receives-new-fda-pdufa-date-for-investigational-palovarotene-for-the-treatment-of-people-with-fop/ 2023-03-17T11:57:07+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/fda-approves-expanded-indication-for-telixs-illuccix-to-include-patient-selection-for-psma-directed-radioligand-therapy/ 2023-03-17T11:59:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/prelude-therapeutics-announces-clinical-trial-collaboration-with-beigene-to-evaluate-prt2527-in-combination-with-zanubrutinib-in-hematologic-cancers/ 2023-03-17T12:00:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/alphamab-oncology-announces-the-first-patient-dosed-in-the-phase-i-trial-of-anti-her2-bispecific-adc-jskn003/ 2023-03-17T12:03:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma/ 2023-03-17T12:04:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/relief-therapeutics-provides-update-from-collaboration-partner-on-olpruva/ 2023-03-17T12:19:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/gilead-exercises-option-to-license-nurixs-irak4-targeted-protein-degrader-development-candidate-nx-0479/ 2023-03-23T12:00:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/biontech-and-oncoc4-announce-strategic-collaboration-to-co-develop-and-commercialize-novel-checkpoint-antibody-in-multiple-solid-tumor-indications/ 2023-03-23T12:01:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medicine-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis/ 2023-03-23T12:03:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/meet-boehringer-ingelheim-genentech-apexigen-more-at-the-5th-cell-engager-summit-2023/ 2023-03-24T11:09:44+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/Pharma-J-CET-Newsletter-1.png http://www.pharmajournalist.com/wp-content/uploads/2023/03/Pharma-J-CET-Newsletter-1.png http://www.pharmajournalist.com/moderna-and-generation-bio-announce-strategic-collaboration-to-develop-non-viral-genetic-medicines/ 2023-03-24T11:15:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/ono-enters-into-a-drug-discovery-collaboration-agreement-with-molcure-to-discover-and-develop-innovative-antibody-drugs-for-multiple-targets-utilizing-molcures-ai-driven-platform-technology/ 2023-03-24T11:17:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/ono-enters-into-a-drug-discovery-collaboration-agreement-with-macomics-to-develop-macrophage-targeting-antibody-therapy-for-the-treatment-of-cancer/ 2023-03-24T11:18:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/curia-collaborates-with-corning-to-advance-biopharmaceutical-continuous-flow-development-and-manufacturing-programs/ 2023-03-24T11:19:53+00:00 https://pharmajournalist.com/wp-content/uploads/2021/08/Curia_Rensselaer.jpg http://www.pharmajournalist.com/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma/ 2023-03-24T11:20:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/invitae-and-deerfield-management-partner-to-create-novel-therapeutics-for-rare-diseases/ 2023-03-24T11:22:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/hovione-and-laxxon-medical-establish-an-agreement-for-the-cgmp-production-of-3d-screen-printed-pharmaceutical-applications/ 2023-03-24T11:23:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/jacobio-announces-clinical-collaboration-to-evaluate-cd73-monoclonal-antibody-jab-bx102-in-combination-with-keytruda-pembrolizumab-for-patients-with-cancer/ 2023-03-24T11:25:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-young-children-with-ultra-rare-form-of-high-cholesterol/ 2023-03-24T11:29:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/dupixent-dupilumab-demonstrates-potential-to-become-first-biologic-to-treat-copd-by-showing-significant-reduction-in-exacerbations-in-pivotal-trial/ 2023-03-24T11:30:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/roche-announces-collaboration-with-lilly-to-enhance-early-diagnosis-of-alzheimers-disease/ 2023-03-24T11:32:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/marinus-pharmaceuticals-receives-fda-orphan-drug-designation-for-ganaxolone-in-the-treatment-of-lennox-gastaut-syndrome/ 2023-03-24T11:34:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/marinus-pharmaceuticals.jpg http://www.pharmajournalist.com/hovione-and-ripple-enter-strategic-partnership-to-expand-epidel-platform-into-non-ophthalmic-space/ 2023-03-24T11:36:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/coya-therapeutics-inc-announces-an-agreement-with-dr-reddys-laboratories-ltd/ 2023-03-24T11:37:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/syneos-health-collaborates-with-microsoft-to-accelerate-ai-across-the-clinical-to-commercial-continuum/ 2023-03-24T11:38:49+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Syneos-Health-Logo.png http://www.pharmajournalist.com/processa-pharmaceuticals-announces-first-patient-dosed-in-the-300-mg-dose-group-with-next-generation-chemotherapy-capecitabine/ 2023-03-24T11:40:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/predictive-oncology-and-cancer-research-horizons-have-partnered-to-pursue-development-of-cancer-drugs/ 2023-03-24T11:42:40+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ipsen-receives-new-fda-pdufa-date-for-investigational-palovarotene-for-the-treatment-of-people-with-fop-2/ 2023-03-24T11:44:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/biohaven-acquires-exclusive-license-for-oral-brain-penetrant-dual-tyk2-jak1-inhibitor-for-immune-mediated-brain-disorders/ 2023-03-24T11:45:43+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Biohaven-Pharma-Logo.png http://www.pharmajournalist.com/invisishield-technologies-collaborates-with-gladstone-institutes-to-accelerate-development-of-intranasal-preventatives-against-sars-cov-2-influenza-and-rsv/ 2023-03-24T11:47:05+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/incyte-announces-fda-approval-of-zynyz-retifanlimab-dlwr-for-the-treatment-of-metastatic-or-recurrent-locally-advanced-merkel-cell-carcinoma-mcc/ 2023-03-24T11:48:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/dewpoint-therapeutics-partners-with-novo-nordisk-to-explore-the-field-of-biomolecular-condensates-to-treat-insulin-resistance-and-diabetes-progression/ 2023-03-24T11:50:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/arrowhead-receives-fda-fast-track-designation-for-aro-apoc3/ 2023-03-24T11:51:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/arrowhead-pharma-logo.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-and-arsenal-biosciences-collaborate-to-support-clinical-manufacturing-of-autologous-t-cell-therapies/ 2023-03-30T10:28:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/evotec-and-bristol-myers-squibb-extend-and-expand-strategic-neurodegeneration-partnership/ 2023-03-30T10:30:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/06/evotec.jpg http://www.pharmajournalist.com/regeneron-and-sonoma-biotherapeutics-announce-collaboration-to-discover-develop-and-commercialize-treg-cell-therapies-for-autoimmune-diseases/ 2023-03-30T10:31:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/moderna-finalizes-agreement-with-the-government-of-the-republic-of-kenya-to-establish-an-mrna-manufacturing-facility/ 2023-03-31T10:38:42+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Moderna.jpg http://www.pharmajournalist.com/lupus-research-alliance-unites-the-u-s-food-drug-administration-fda-lupus-community-to-launch-novel-public-private-partnership/ 2023-03-31T10:40:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/thea-open-innovation-and-galimedix-announce-strategic-partnership-to-develop-and-commercialize-gal-101-a-phase-2-3-ready-small-molecule-to-treat-ophthalmic-indications-with-high-unmet-medical-need/ 2023-03-31T10:42:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/libtayo-cemiplimab-in-combination-with-chemotherapy-approved-by-european-commission-for-the-first-line-treatment-of-advanced-pd-l1-positive-nsclc/ 2023-03-31T10:43:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/fda-grants-full-approval-to-keytruda-pembrolizumab-for-advanced-msi-h-or-dmmr-solid-tumors-in-adults-and-children/ 2023-03-31T10:46:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp-a-novel-first-in-class-medicine-to-treat-fungal-infection/ 2023-03-31T12:31:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/license-agreement-with-kym-biosciences-for-cmg901-a-claudin-18-2-antibody-drug-conjugate-completed/ 2023-03-31T12:32:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/galapagos-and-novalix-enter-into-an-integrated-drug-discovery-collaboration/ 2023-03-31T12:34:17+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/avadel-pharmaceuticals-enters-into-royalty-agreement-with-rtw-investments-for-up-to-75-million/ 2023-03-31T12:35:55+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/aquestive-therapeutics-expands-license-and-supply-agreement-with-pharmanovia-for-libervant-diazepam-buccal-film-to-additional-global-markets/ 2023-03-31T12:37:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/covant-and-boehringer-ingelheim-collaborate-to-develop-a-novel-adar1-inhibitor-for-use-in-cancer-patients/ 2023-03-31T12:38:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/tevas-digital-health-collaboration-with-rimidi-expands-to-include-respiratory-monitoring-program-integration-with-a-large-u-s-health-system/ 2023-03-31T12:39:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/vertex-and-crispr-therapeutics-announce-licensing-agreement-to-accelerate-development-of-vertexs-hypoimmune-cell-therapies-for-the-treatment-of-type-1-diabetes/ 2023-03-31T12:41:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-opens-cell-therapy-facility-at-university-of-california-san-francisco-to-accelerate-development-of-breakthrough-therapies/ 2023-03-31T12:43:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/thermo-fisher-scientific.jpg http://www.pharmajournalist.com/genesiscare-and-premit-collaborate-to-identify-and-pursue-clinical-research-opportunities-in-theranostics-and-molecular-imaging/ 2023-03-31T12:44:46+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/takeda-receives-approval-to-manufacture-and-market-entyvio-subcutaneous-injection-in-japan-for-the-maintenance-treatment-of-moderate-to-severe-ulcerative-colitis/ 2023-03-31T12:46:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/cybeats-announces-trial-evaluation-with-one-of-the-worlds-largest-software-companies/ 2023-03-31T12:48:14+00:00 https://pharmajournalist.com/wp-content/uploads/2023/03/Cybeats-Logo.png http://www.pharmajournalist.com/curia-collaborates-with-corning-to-advance-biopharmaceutical-continuous-flow-development-and-manufacturing-programs-2/ 2023-03-31T12:49:27+00:00 https://pharmajournalist.com/wp-content/uploads/2021/08/Curia_Rensselaer.jpg http://www.pharmajournalist.com/oncovent-a-subsidiary-of-hepalink-enters-into-a-license-and-distribution-agreement-with-orient-europharma-for-the-immunotherapeutic-candidate-oregovomab/ 2023-03-31T12:51:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/get-a-glimpse-from-providence-kp-and-cvs-health-leaders-of-what-you-can-learn-from-their-sessions-at-reuters-events-digital-health/ 2023-04-05T11:55:15+00:00 https://pharmajournalist.com/wp-content/uploads/2022/12/DH-banner-600-x-400.jpg http://www.pharmajournalist.com/fda-accepts-pfizers-supplemental-new-drug-applications-for-braftovi-mektovi/ 2023-04-06T00:05:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sandoz-receives-approval-by-european-commission-for-hyrimoz-adalimumab-high-concentration-formulation/ 2023-04-06T00:06:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/biontech-and-dualitybio-form-global-strategic-partnership-to-accelerate-development-of-differentiated-antibody-drug-conjugate-therapeutics-for-solid-tumors/ 2023-04-06T00:07:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-c/ 2023-04-06T00:09:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/novartis-entresto-receives-positive-chmp-opinion-for-pediatric-heart-failure/ 2023-04-06T00:11:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/panbela-regains-worldwide-rights-to-develop-and-commercialize-flynpovitm-in-patients-with-familial-adenomatous-polyposis-fap/ 2023-04-13T10:13:21+00:00 https://pharmajournalist.com/wp-content/uploads/2023/04/PANBELA-Therapeutics-logo.jpg http://www.pharmajournalist.com/centogene-extends-strategic-partnership-with-takeda-to-continue-providing-access-to-genetic-testing-for-patients-with-lysosomal-storage-disorders/ 2023-04-13T10:16:50+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/Centogene-AG-Logo.png http://www.pharmajournalist.com/cognizant-and-boehringer-ingelheim-collaborate-on-unified-cloud-platform-to-speed-the-delivery-of-life-saving-therapies/ 2023-04-13T10:18:15+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/ips-heart-receives-fda-rare-pediatric-drug-designations-for-both-of-its-stem-cell-drugs-for-duchenne-muscular-dystrophy/ 2023-04-14T12:01:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/twist-bioscience-launches-tcr-and-car-libraries-to-enable-the-development-of-cell-therapies/ 2023-04-14T12:03:24+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/Twist-Bioscience-logo.jpg http://www.pharmajournalist.com/tiziana-life-sciences-to-pursue-development-of-intranasal-foralumab-for-the-treatment-of-long-covid/ 2023-04-14T12:04:43+00:00 https://pharmajournalist.com/wp-content/uploads/2021/02/Tiziana-Logo.png http://www.pharmajournalist.com/pharmalex-expands-australia-footprint-through-merger-plan-with-pharmacovigilance-leader-cpharm/ 2023-04-14T12:08:38+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/imaginab-executes-new-license-and-supply-agreement-for-cd8-immunopet-technology-with-leucid-bio/ 2023-04-14T12:10:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/ImaginAb-Logo.jpg http://www.pharmajournalist.com/fusion-pharmaceuticals-announces-ind-clearance-for-fpi-2068-a-jointly-developed-novel-targeted-alpha-therapy/ 2023-04-14T12:12:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/insilico-medicine-successfully-discovered-potent-selective-and-orally-bioavailable-small-molecule-inhibitor-of-cdk8-using-generative-ai/ 2023-04-14T12:14:47+00:00 https://pharmajournalist.com/wp-content/uploads/2023/04/Insilico-Medicine.png http://www.pharmajournalist.com/biogen-exercises-option-with-denali-to-develop-and-commercialize-antibody-transport-vehicle-program-targeting-amyloid-beta/ 2023-04-14T12:15:58+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/oncotelic-therapeutics-and-vectara-announce-strategic-partnership-to-transform-pharmaceutical-research-with-large-language-model-technology/ 2023-04-21T12:34:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/angle-announces-partnership-with-bioview/ 2023-04-21T12:35:37+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-genentechs-polivy-in-combination-with-r-chp-for-people-with-certain-types-of-previously-untreated-diffuse-large-b-cell-lymphoma/ 2023-04-21T12:37:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-moderately-to-severely-active-crohns-disease/ 2023-04-21T12:39:48+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/bio-techne-and-lunaphore-establish-strategic-partnership-to-develop-the-first-fully-automated-same-slide-spatial-multiomics-solution/ 2023-04-21T12:43:21+00:00 https://pharmajournalist.com/wp-content/uploads/2023/04/Bio_Techne_Corporation_Lunaphore_Comet_instrument.jpg https://pharmajournalist.com/wp-content/uploads/2023/04/Bio_Techne_Corporation_Lunaphore_Comet_instrument.jpg http://www.pharmajournalist.com/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences/ 2023-04-21T12:45:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/join-deloitte-nhs-and-more-to-discuss-business-role-in-health-equity/ 2023-04-26T12:35:02+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/Reuters-Events-Logo.png http://www.pharmajournalist.com/fda-grants-accelerated-approval-for-qalsody-tofersen-for-sod1-als-a-major-scientific-advancement-as-the-first-treatment-to-target-a-genetic-cause-of-als/ 2023-04-28T08:22:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/11/Biogen.jpg http://www.pharmajournalist.com/boehringer-ingelheim-inaugurates-largest-european-development-centre-for-biotechnology/ 2023-04-28T08:23:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/lantheus-and-point-biopharma-announce-fda-grants-fast-track-designation-for-%c2%b9%e2%81%b7%e2%81%b7lu-pnt2002-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/ 2023-04-28T08:27:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/alx-oncology-announces-clinical-trial-collaboration-with-sanofi-to-evaluate-evorpacept-in-combination-with-sarclisa-isatuximab-irfc-in-patients-with-multiple-myeloma/ 2023-04-28T08:28:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/ALX-Oncology-Logo.jpg http://www.pharmajournalist.com/fda-approves-gsks-arexvy-the-worlds-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2023-05-05T08:18:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/arthex-biotech-announces-closing-of-e42-m-series-b-financing-to-advance-atx-01-its-novel-treatment-for-myotonic-dystrophy-type-1-dm1/ 2023-05-05T08:19:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/roche-launches-institute-of-human-biology-to-accelerate-breakthroughs-in-rd-by-unlocking-the-potential-of-human-model-systems/ 2023-05-05T08:20:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/kamada-announces-u-s-fda-approval-of-its-application-to-manufacture-cytogam-at-the-companys-facility-in-israel/ 2023-05-05T08:21:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/magenta-therapeutics-and-dianthus-therapeutics-announce-merger-agreement/ 2023-05-05T08:23:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/vertexs-kalydeco-ivacaftor-receives-fda-approval-for-treatment-of-cystic-fibrosis-in-infants-as-young-as-1-month-old/ 2023-05-05T08:25:28+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/forge-biologics-and-labcorp-announce-strategic-aav-gene-therapy-development-and-manufacturing-collaboration/ 2023-05-05T08:26:50+00:00 https://pharmajournalist.com/wp-content/uploads/2021/07/Forge_Biologics.jpg http://www.pharmajournalist.com/bristol-myers-squibb-receives-european-commission-approval-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy/ 2023-05-05T08:28:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/brightpath-biotherapeutics-and-artisan-bio-announce-research-and-licensing-agreement-to-accelerate-development-of-brightpaths-novel-allogeneic-ipsc-derived-cell-therapy-platform-across-multiple-indi/ 2023-05-05T08:29:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/full-life-technologies-announces-land-purchase-in-belgium-to-establish-gmp-manufacturing-facility-for-radiopharmaceutical-drug-production/ 2023-05-05T08:32:20+00:00 https://pharmajournalist.com/wp-content/uploads/2023/05/Full-Life-Technologies-Full-Life.png http://www.pharmajournalist.com/amphista-therapeutics-achieves-first-discovery-milestone-in-collaboration-with-bristol-myers-squibb/ 2023-05-05T08:34:52+00:00 https://pharmajournalist.com/wp-content/uploads/2023/05/Amphista_Therapeutics_Logo.jpg http://www.pharmajournalist.com/sobi-to-acquire-cti-biopharma-corp-enhancing-sobis-position-in-rare-haematology/ 2023-05-12T07:43:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/sobi.png http://www.pharmajournalist.com/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd/ 2023-05-12T07:44:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/bayer-and-bicycle-therapeutics-enter-strategic-collaboration-for-development-of-novel-targeted-radionuclide-therapies-in-oncology/ 2023-05-12T07:45:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease/ 2023-05-12T07:47:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/thermo-fisher-scientific-pfizer-partner-to-expand-localized-access-to-next-generation-sequencing-based-testing-for-cancer-patients-in-international-markets/ 2023-05-12T07:48:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/promis-neurosciences-announces-fda-clearance-of-investigational-new-drug-ind-application-for-pmn310-in-alzheimers-disease/ 2023-05-12T07:50:25+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/promis-neurosciences-logo.jpg http://www.pharmajournalist.com/curevac-announces-dosing-of-first-participant-in-combined-phase-1-2-study-of-multivalent-modified-influenza-vaccine-candidates-developed-in-collaboration-with-gsk/ 2023-05-12T07:51:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Curevac-logo.png http://www.pharmajournalist.com/fda-accepts-application-for-roches-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/ 2023-05-12T07:53:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/ucb-and-ariceum-therapeutics-sign-a-strategic-research-collaboration-to-discover-new-modalities-for-the-treatment-of-immune-related-diseases-and-cancer/ 2023-05-12T07:55:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/otsuka-and-lundbeck-announce-fda-approval-of-supplemental-new-drug-application-snda-for-rexulti-brexpiprazole-for-the-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-dis/ 2023-05-12T07:57:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/uniqure-announces-sale-of-royalty-interest-in-hemgenix-for-up-to-400-million/ 2023-05-17T11:37:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/uniqure.jpg http://www.pharmajournalist.com/fda-grants-priority-review-of-tak-755-for-the-treatment-of-congenital-thrombotic-thrombocytopenic-purpura-cttp/ 2023-05-17T11:39:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/wuxi-biologics-announces-manufacturing-partnership-with-inflarx-to-advance-gohibic-for-the-treatment-of-certain-critically-ill-covid-19-patients/ 2023-05-17T11:40:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/wuxi-biologics-logo.png http://www.pharmajournalist.com/galera-announces-fda-orphan-drug-designation-granted-to-rucosopasem-for-pancreatic-cancer/ 2023-05-19T09:55:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/antengene-announces-clearance-of-u-s-ind-for-the-phase-i-trial-of-first-in-class-anti-cd24-monoclonal-antibody-atg-031/ 2023-05-19T09:57:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/04/Antengene-Logo.jpg http://www.pharmajournalist.com/revvity-announces-new-license-agreement-for-next-generation-base-editing-technology/ 2023-05-19T09:59:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/asieris-deepens-strategic-partnership-with-uroviu-to-further-develop-integrated-diagnosis-and-treatment-platform-for-bladder-cancer/ 2023-05-19T10:00:08+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/sony-and-astellas-enter-into-collaborative-research-agreement-to-discover-a-novel-adc-platform-for-the-oncology-field/ 2023-05-19T10:02:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation/ 2023-05-19T10:04:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/ucb-and-veeva-collaborate-to-advance-the-patient-experience-in-clinical-trials/ 2023-05-24T14:36:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/inovio-announces-orphan-drug-designation-for-ino-3107-for-the-treatment-of-recurrent-respiratory-papillomatosis-from-the-european-commission/ 2023-05-24T14:38:44+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Inovio-pharma.jpg http://www.pharmajournalist.com/fda-approves-abrysvo-pfizers-vaccine-for-the-prevention-of-respiratory-syncytial-virus-rsv-in-older-adults/ 2023-06-01T11:55:02+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/novo-nordisk-and-life-edit-therapeutics-establish-multi-target-collaboration-to-discover-and-develop-gene-editing-therapies-for-rare-and-cardiometabolic-diseases/ 2023-06-01T11:57:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/sun-pharma-and-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-commercializing-specialty-product-nidlegy-in-europe-australia-and-new-zealand/ 2023-06-01T11:59:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/SunPharma.jpg http://www.pharmajournalist.com/positive-phase-2-data-of-novel-investigational-anti-cd40l-antibody-frexalimab-show-significantly-reduced-disease-activity-in-relapsing-multiple-sclerosis/ 2023-06-02T10:16:31+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/lynparza-plus-abiraterone-approved-in-the-us-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer/ 2023-06-02T10:18:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/index-pharmaceuticals-announces-license-agreement-with-viatris-japan-to-develop-and-commercialize-cobitolimod-in-japan/ 2023-06-02T10:19:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/InDex-Pharmaceuticals-logo.png http://www.pharmajournalist.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-the-japanese-patent-office-for-repirinast-and-the-treatment-of-ckd/ 2023-06-02T10:21:19+00:00 https://pharmajournalist.com/wp-content/uploads/2021/05/Algernon-Pharma-Logo.png http://www.pharmajournalist.com/analog-pharma-and-dipharma-announce-us-fda-approval-of-abbreviated-new-drug-application-anda-of-20-mg-generic-nitisinone-capsules-temperature-stable/ 2023-06-02T10:22:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/vazyme-signs-global-strategic-cooperation-agreement-with-azenta/ 2023-06-06T11:07:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/injectafer-approved-in-the-u-s-for-the-treatment-of-iron-deficiency-in-adult-patients-with-heart-failure/ 2023-06-06T11:10:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/nrx-pharmaceuticals-lotus-pharmaceuticals-and-alvogen-inc-announce-collaboration-to-develop-and-commercialize-nrx-101/ 2023-06-06T11:11:52+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biondvax-signs-exclusive-license-agreement-for-development-and-commercialization-of-a-novel-anti-il-17-antibody-for-treatment-of-autoimmune-and-inflammatory-diseases-including-psoriasis/ 2023-06-06T11:13:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology/ 2023-06-06T11:14:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/lonza-to-acquire-synaffix-and-strengthen-antibody-drug-conjugates-offering/ 2023-06-06T11:15:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/lonza.jpg http://www.pharmajournalist.com/dtx-pharma-receives-fda-orphan-drug-designation-for-dtx-1252-for-the-treatment-of-charcot-marie-tooth-disease-type-1a-cmt1a/ 2023-06-08T11:13:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care/ 2023-06-08T11:14:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis/ 2023-06-16T11:47:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/astellas-and-cullgen-enter-into-strategic-collaboration-and-option-agreement-to-advance-innovative-targeted-protein-degraders/ 2023-06-16T11:48:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/fda-approved-utidelone-injectable-utd1-phase-2-3-multi-national-clinical-trial-for-non-small-cell-lung-cancer/ 2023-06-16T11:50:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sandoz-introduces-act4biosimilars-action-plan-to-accelerate-patient-access-to-biosimilar-medicines/ 2023-06-16T11:52:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/fresenius-kabi-launches-vasopressin-injection-usp-expanding-u-s-critical-care-portfolio/ 2023-06-16T11:54:55+00:00 https://pharmajournalist.com/wp-content/uploads/2023/06/Vasopressin.jpg https://pharmajournalist.com/wp-content/uploads/2023/06/Vasopressin.jpg http://www.pharmajournalist.com/charles-river-and-curigin-collaborate-to-produce-oncolytic-rnai-gene-therapy/ 2023-06-16T11:56:52+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/talaris-therapeutics-and-tourmaline-bio-announce-merger-agreement/ 2023-06-23T13:18:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia/ 2023-06-23T13:20:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/aslan-pharmaceuticals-enters-into-a-strategic-licensing-deal-with-zenyaku-kogyo-for-the-development-and-commercialization-of-eblasakimab-in-japan/ 2023-06-23T13:22:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology/ 2023-06-23T13:35:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/fda-approves-jardiance-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older/ 2023-06-23T13:39:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/ultragenyx-opens-new-gene-therapy-manufacturing-facility-in-bedford-continuing-its-expansion-in-massachusetts/ 2023-06-23T13:41:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Ultragenyxlogo.gif http://www.pharmajournalist.com/hear-from-verve-biogen-entrada-tx-on-oligonucleotide-development/ 2023-06-26T22:57:41+00:00 https://pharmajournalist.com/wp-content/uploads/2023/06/Oligos-PR-Marketing-Speakers.png http://www.pharmajournalist.com/wp-content/uploads/2023/06/Oligos-PR-Marketing-Speakers.png http://www.pharmajournalist.com/gsk-receives-us-fda-fast-track-designation-for-investigational-vaccine-against-gonorrhoea/ 2023-06-28T11:17:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-accepts-pfizers-application-for-hemophilia-b-gene-therapy-fidanacogene-elaparvovec/ 2023-06-28T11:18:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes/ 2023-06-28T11:20:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/xentria-and-meitheal-pharmaceuticals-announce-exclusive-licensing-agreement-for-xtmab-16-in-north-america/ 2023-06-28T11:22:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/innovent-and-remegen-enter-into-clinical-trial-collaboration-investigating-combination-therapy-of-tyvyt-sintilimab-injection-and-novel-adc-candidates-for-advanced-solid-tumors-in-china/ 2023-06-28T11:45:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/brii-biosciences-announces-entry-into-definitive-agreements-from-sale-of-its-equity-interest-in-qpex-biopharma-and-acquiring-exclusive-global-rights-for-brii-693/ 2023-06-28T11:46:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sangamo-therapeutics-and-voyager-therapeutics-enter-license-agreement-for-epigenetic-regulation-treatment-of-prion-disease/ 2023-06-30T11:59:54+00:00 https://pharmajournalist.com/wp-content/uploads/2018/03/Sangamo-Therapeutics.jpg http://www.pharmajournalist.com/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-with-chemotherapy-as-neoadjuvant-treatment-of-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence-in-pati/ 2023-06-30T12:00:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/lilly-to-acquire-sigilon-therapeutics/ 2023-06-30T12:03:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/gsk-completes-acquisition-of-bellus-health/ 2023-06-30T12:05:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/fda-issues-complete-response-letter-crl-for-aflibercept-8-mg-biologics-license-application-solely-due-to-an-ongoing-review-of-inspection-findings-at-a-third-party-filler/ 2023-06-30T12:07:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/seven-manufacturers-sign-sublicence-agreements-with-the-medicines-patent-pool-to-produce-generic-versions-of-shionogis-covid-19-oral-antiviral-ensitrelvir-to-increase-access-in-low-and-middle-incom/ 2023-06-30T12:09:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tonix-pharmaceuticals-completes-acquisition-of-two-fda-approved-marketed-migraine-products/ 2023-07-04T14:42:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/tonix-pharmaceuticals.png http://www.pharmajournalist.com/baudax-bio-acquires-teraimmune/ 2023-07-04T14:45:54+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/astellas-announces-fda-grants-priority-review-for-zolbetuximab-biologics-license-application/ 2023-07-07T08:49:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/lifera-sanofi-and-arabio-sign-mou-to-manufacture-and-supply-vaccines-in-saudi-arabia-boosting-local-production-with-a-new-state-of-the-art-manufacturing-facility/ 2023-07-07T08:51:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/vbi-vaccines-and-brii-biosciences-expand-hepatitis-b-partnership-to-address-both-prevention-and-treatment-in-license-and-collaboration-agreements-for-up-to-437-million-plus-royalties/ 2023-07-07T08:53:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/VBI-Vaccines-Logo.png http://www.pharmajournalist.com/sk-bioscience-government-pharmaceutical-organization-sign-memorandum-of-understanding-to-strengthen-vaccine-infrastructure-in-thailand/ 2023-07-07T08:56:34+00:00 https://pharmajournalist.com/wp-content/uploads/2023/07/SK-bioscience-Sign-Memorandum.jpg https://pharmajournalist.com/wp-content/uploads/2023/07/SK-bioscience-Sign-Memorandum.jpg http://www.pharmajournalist.com/f-star-an-invox-company-announces-strategic-collaboration-and-licence-agreement-with-takeda-to-discover-and-develop-next-generation-multi-specific-antibodies/ 2023-07-07T08:59:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/european-commission-approves-orkambi-lumacaftor-ivacaftor-for-the-treatment-of-children-with-cystic-fibrosis-ages-1-to/ 2023-07-07T09:01:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/tiumbio-and-hansoh-pharma-announce-clinical-trial-approval-of-hs-10518-tu2670-from-nmpa-in-china/ 2023-07-07T09:05:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/clinical-trial.jpg http://www.pharmajournalist.com/biocytogen-pharmaceuticals-enters-into-license-agreement-with-pheon-therapeutics/ 2023-07-07T09:09:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/entrada-to-receive-224-million-upfront-payment-and-26-million-equity-investment/ 2023-07-14T12:17:17+00:00 https://pharmajournalist.com/wp-content/uploads/2023/06/Oligos-PR-Marketing-Speakers.png http://www.pharmajournalist.com/gilead-partners-with-chai-and-penta-to-improve-treatment-and-adherence-rates-among-children-with-hiv-in-low-and-middle-income-countries/ 2023-07-14T12:18:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/beigene-announces-fda-acceptance-of-snda-for-fifth-brukinsa-indication/ 2023-07-14T12:24:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab/ 2023-07-14T12:27:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/lianbio-announces-clinical-supply-agreement-with-astrazeneca-in-china-to-evaluate-bbp-398-in-combination-with-osimertinib-in-patients-with-non-small-cell-lung-cancer-with-egfr-mutations/ 2023-07-14T12:28:31+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/innocare-and-arrivent-announce-clinical-development-collaboration/ 2023-07-14T12:29:48+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/theracosbio-announces-commercial-availability-of-brenzavvy-bexagliflozin-for-the-treatment-of-adults-with-type-2-diabetes/ 2023-07-14T12:33:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/drug-discovery.jpg http://www.pharmajournalist.com/astellas-completes-acquisition-of-iveric-bio/ 2023-07-14T12:34:59+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/fda-approves-expanded-indication-for-novartis-leqvio-inclisiran-to-include-treatment-of-adults-with-high-ldl-c-and-who-are-at-increased-risk-of-heart-disease/ 2023-07-14T12:36:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/exclusive-interview-with-astrazeneca-on-the-future-of-oligonucleotide-drug-development/ 2023-07-14T12:48:18+00:00 https://pharmajournalist.com/wp-content/uploads/2023/07/Oligonucleotides-Speaker-Image.png https://pharmajournalist.com/wp-content/uploads/2023/07/Oligonucleotides-Speaker-Image.png http://www.pharmajournalist.com/ipsen-announces-european-commission-decision-on-palovarotene-for-the-treatment-of-fop/ 2023-07-20T12:22:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/biocryst-selects-er-kim-pharmaceuticals-as-commercial-partner-for-orladeyo-berotralstat-in-turkey/ 2023-07-20T12:25:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/biocryst-pharma.jpg http://www.pharmajournalist.com/eleven-therapeutics-announces-research-collaboration-with-novo-nordisk-to-discover-cell-specific-carriers-of-nucleic-acid-therapeutics/ 2023-07-20T12:27:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-veklury-remdesivir-for-covid-19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis/ 2023-07-20T12:28:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/vanflyta-first-flt3-inhibitor-approved-in-the-u-s-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml/ 2023-07-21T09:13:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/teva-pharmaceuticals-and-alvotech-provide-update-on-strategic-biosimilars-partnership/ 2023-07-26T07:47:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/jardiance-empagliflozin-approved-in-the-eu-for-the-treatment-of-adults-with-chronic-kidney-disease/ 2023-07-26T07:51:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/astellas-and-peptidream-enter-into-research-collaboration-and-license-agreement-to-discover-novel-targeted-protein-degraders/ 2023-07-26T07:53:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million/ 2023-07-26T07:54:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/immunogen-announces-multi-target-license-and-option-agreement-with-immunobiochem-to-develop-next-generation-antibody-drug-conjugates/ 2023-07-26T07:56:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Immunogen-Logo.png http://www.pharmajournalist.com/sandoz-receives-positive-chmp-opinion-for-multiple-sclerosis-biosimilar-natalizumab/ 2023-07-26T07:58:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/alnylam-announces-partnership-with-roche-to-co-develop-and-co-commercialize-zilebesiran-an-investigational-rnai-therapeutic-for-the-treatment-of-hypertension-in-patients-with-high-cardiovascular-risk/ 2023-07-26T07:59:43+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/alnylam-pharmaceuticals_logo.jpg http://www.pharmajournalist.com/insilicotrials-and-axoltis-pharma-collaborate-to-advance-therapeutic-solutions-for-neurological-disorders/ 2023-07-28T09:13:43+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/european-commission-approves-gileads-trodelvy-for-pre-treated-hr-her2-metastatic-breast-cancer/ 2023-07-28T09:15:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/abbvie-and-calibr-expand-strategic-collaboration-to-advance-several-preclinical-and-early-stage-clinical-assets/ 2023-07-28T09:17:28+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/kriya-announces-150-million-addition-to-its-series-c-bringing-total-round-to-over-430-million-to-further-its-mission-of-delivering-gene-therapies-for-prevalent-diseases/ 2023-07-28T09:19:15+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/hummingbird-bioscience-initiates-hmbd-001-phase-ib-trials-in-australia-and-partners-with-omico-to-accelerate-clinical-development/ 2023-07-28T09:22:22+00:00 https://pharmajournalist.com/wp-content/uploads/2020/02/Hummingbird-Bioscience-Logo.jpg http://www.pharmajournalist.com/lianbio-partner-tarsus-pharmaceuticals-announces-u-s-fda-approval-of-xdemvy-lotilaner-ophthalmic-solution-0-25-for-the-treatment-of-demodex-blepharitis/ 2023-07-28T09:24:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ayala-pharmaceuticals-and-biosight-enter-into-definitive-merger-agreement/ 2023-07-28T09:28:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/re-designing-u-s-health-insurance/ 2023-07-28T09:33:54+00:00 https://pharmajournalist.com/wp-content/uploads/2022/01/Reuters-Events-Logo.png http://www.pharmajournalist.com/zuellig-pharma-singapore-and-gsk-establish-vaccine-distribution-hub-to-improve-asias-access-to-vaccines/ 2023-08-03T10:57:25+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/zuelligpharma_GSK-Vaccine.jpg https://pharmajournalist.com/wp-content/uploads/2023/08/zuelligpharma_GSK-Vaccine.jpg http://www.pharmajournalist.com/redhill-biopharma-announces-talicia-approved-in-the-united-arab-emirates-and-first-commercial-order-outside-the-u-s/ 2023-08-03T10:59:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/redhill-biopharma-logo.png http://www.pharmajournalist.com/allarity-therapeutics-and-fivephusion-announce-collaboration-to-support-clinical-development-of-deflexifol-with-drp-companion-diagnostics/ 2023-08-03T11:02:53+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/solu-therapeutics-debuts-with-31-million-in-seed-funding-to-unlock-antibody-intractable-cell-surface-targets/ 2023-08-03T11:04:51+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older/ 2023-08-04T08:07:21+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors/ 2023-08-04T08:08:30+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/ionis-enters-collaboration-to-advance-next-generation-program-targeting-lpa-for-cardiovascular-disease/ 2023-08-04T08:10:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ionis-pharma.jpg http://www.pharmajournalist.com/fda-approves-lonsurf-trifluridine-tipiracil-in-combination-with-bevacizumab-for-adult-patients-with-metastatic-colorectal-cancer-mcrc/ 2023-08-04T08:13:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-abm-1310-for-the-treatment-of-patients-with-glioblastoma-harboring-braf-v600-mutation/ 2023-08-04T08:15:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sygnature-discovery-accelerates-global-growth-with-major-north-american-acquisition/ 2023-08-04T08:20:07+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/NuChem-Sciences.jpg http://www.pharmajournalist.com/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120/ 2023-08-04T08:22:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/genscript-biotech-and-t-maximum-biotech-form-strategic-alliance-on-cgmp-sgrna/ 2023-08-10T12:06:40+00:00 https://pharmajournalist.com/wp-content/uploads/2021/12/GenScript-ProBio.jpg http://www.pharmajournalist.com/regeneron-to-acquire-decibel-therapeutics-strengthening-gene-therapy-and-hearing-loss-programs/ 2023-08-10T12:08:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/celmatix-and-ache-laboratorios-announce-collaboration-to-investigate-a-novel-melatonin-receptor-agonists-for-womens-health/ 2023-08-10T12:10:09+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agc-biologics-completes-expansion-at-milan-cell-and-gene-therapy-development-and-manufacturing-site/ 2023-08-10T12:11:29+00:00 https://pharmajournalist.com/wp-content/uploads/2018/05/AGC-Biologics.jpg http://www.pharmajournalist.com/genscript-expands-peptide-production-capabilities-to-include-neoantigen-peptides-and-apis/ 2023-08-10T12:14:50+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/GenScript_Biotech_peptides_manufacturing.jpg https://pharmajournalist.com/wp-content/uploads/2023/08/GenScript_Biotech_peptides_manufacturing.jpg http://www.pharmajournalist.com/astex-expands-drug-discovery-collaboration-with-msd/ 2023-08-10T12:16:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-approves-ipsens-sohonos-palovarotene-capsules-the-first-and-only-treatment-for-people-with-fibrodysplasia-ossificans-progressiva/ 2023-08-18T11:45:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/day-one-announces-vrk1-license-agreement-and-research-collaboration-with-sprint-bioscience/ 2023-08-18T11:49:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/venatorx-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-cefepime-taniborbactam-to-treat-complicated-urinary-tract-infections-cuti-including-pyelonephritis/ 2023-08-18T11:51:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/lilly-completes-acquisition-of-versanis-bio/ 2023-08-18T12:02:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/novartis-completes-acquisition-of-chinook-therapeutics/ 2023-08-18T12:03:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/sandoz-announces-positive-results-from-mylight-phase-lll-study-for-biosimilar-aflibercept/ 2023-08-18T12:05:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/coeptis-therapeutics-completes-exclusive-license-for-allogeneic-immuno-oncology-platform-and-clinical-stage-assets-from-deverra-therapeutics/ 2023-08-18T12:06:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/european-medicines-agency-accepts-iveric-bios-marketing-authorization-application-for-avacincaptad-pegol-for-geographic-atrophy/ 2023-08-18T12:08:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/briacell-awarded-national-cancer-institute-grant-to-advance-its-bria-ots-immunotherapy-for-cancer/ 2023-08-18T12:10:43+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/BriaCell-Logo.png http://www.pharmajournalist.com/bruker-corporation-and-phenomex-inc-announce-definitive-agreement-for-bruker-to-acquire-phenomex-in-all-cash-transaction/ 2023-08-18T12:12:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/artiva-biotherapeutics-announces-fda-clearance-of-ind-for-allonk-cell-therapy-candidate-in-combination-with-rituximab-in-lupus-nephritis/ 2023-08-18T12:14:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/leo-pharma-signs-agreement-to-acquire-timber-pharmaceuticals/ 2023-08-22T11:53:07+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-abrysvo-pfizers-vaccine-for-the-prevention-of-respiratory-syncytial-virus-rsv-in-infants-through-active-immunization-of-pregnant-individuals-32-36-weeks-of-gestational-age/ 2023-08-22T11:55:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/exelixis-and-ipsen-announce-positive-results-from-phase-3-contact-02-pivotal-trial-evaluating-cabozantinib-in-combination-with-atezolizumab-in-metastatic-castration-resistant-prostate-cancer/ 2023-08-22T11:57:10+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/carsgen-collaborates-with-moderna-to-evaluate-ct041-in-combination-with-an-mrna-cancer-vaccine/ 2023-08-22T12:00:29+00:00 https://pharmajournalist.com/wp-content/uploads/2019/11/Carsgen-Therapeutics-Logo.jpg http://www.pharmajournalist.com/fda-approves-veklury-remdesivir-to-treat-covid-19-in-people-with-mild-to-severe-hepatic-impairment-with-no-dose-adjustment/ 2023-08-25T13:39:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/lynparza-olaparibplus-abiraterone-and-prednisolone-approved-in-japan-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer/ 2023-08-25T13:40:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/fda-grants-priority-review-for-xtandi-in-non-metastatic-castration-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence/ 2023-08-25T13:43:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/sk-bioscience-and-vaxxas-enter-joint-development-agreement-for-needle-free-patch-delivery-of-typhoid-vaccine/ 2023-08-25T13:45:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/purify23-registration-now-open/ 2023-08-29T18:14:47+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/Purify-2023-Press-Release.png http://www.pharmajournalist.com/wp-content/uploads/2023/08/Purify-2023-Press-Release.png http://www.pharmajournalist.com/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-xbb-1-5-adapted-covid-19-vaccine-in-the-european-union/ 2023-08-31T08:53:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/roches-tecentriq-becomes-the-first-subcutaneous-anti-pd-l1-cancer-immunotherapy-available-to-patients-in-great-britain-reducing-treatment-time-to-just-minutes/ 2023-08-31T08:54:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/zealand-pharma-announces-designation-of-priority-review-by-the-us-fda-for-dasiglucagon-in-congenital-hyperinsulinism/ 2023-08-31T08:56:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/novo-nordisk-acquires-embark-biotech-including-its-lead-asset-targeting-obesity-and-other-cardiometabolic-diseases/ 2023-08-31T08:57:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/european-commission-approves-roches-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-sma/ 2023-08-31T08:58:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/abbvie-submits-regulatory-applications-to-fda-and-ema-for-risankizumab-skyrizi-in-ulcerative-colitis/ 2023-08-31T08:59:52+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/abbvie.jpg http://www.pharmajournalist.com/7th-ipf-summit-advancing-insights-and-collaboration-in-pulmonary-fibrosis-research-and-therapeutic-development/ 2023-08-31T12:34:06+00:00 https://pharmajournalist.com/wp-content/uploads/2023/07/IPF-Summit-Pharma-Journalist.gif http://www.pharmajournalist.com/calquence-approved-in-china-for-chronic-lymphocytic-leukaemia/ 2023-09-05T09:09:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/amgen-and-horizon-therapeutics-plc-resolve-ftc-lawsuit-clearing-path-to-close-acquisition/ 2023-09-05T09:11:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/gsks-regulatory-submission-accepted-for-review-by-japanese-regulator-for-use-of-nucala-mepolizumab-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2023-09-05T09:12:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/broad-institute-of-mit-and-harvard-announces-a-new-research-alliance-with-novo-nordisk-to-identify-therapeutic-targets-for-type-2-diabetes-and-cardiometabolic-diseases/ 2023-09-07T09:59:19+00:00 https://pharmajournalist.com/wp-content/uploads/2023/09/Broad-Institute.jpg http://www.pharmajournalist.com/apollo-therapeutics-closes-226-5-million-series-c-financing-led-by-patient-square-capital/ 2023-09-07T10:01:13+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/zenas-biopharma-announces-strategic-license-and-collaboration-agreement-with-bristol-myers-squibb-to-develop-and-commercialize-novel-bi-functional-antibody-obexelimab-in-japan-south-korea-taiwan-si/ 2023-09-07T10:02:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/tc-biopharm-announces-grant-funding-in-collaboration-with-queen-mary-university-of-london-qmul/ 2023-09-07T10:04:14+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/mirum-pharmaceuticals-completes-acquisition-of-bile-acid-product-portfolio-for-treatment-of-rare-liver-diseases-from-travere-therapeutics/ 2023-09-07T10:05:53+00:00 https://pharmajournalist.com/wp-content/uploads/2021/04/Mirum-Logo.jpg http://www.pharmajournalist.com/otsuka-collaborates-with-shapetx-to-develop-novel-aav-gene-therapies-for-ocular-diseases/ 2023-09-08T11:18:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/biocytogen-enters-into-antibody-evaluation-option-and-license-agreement-with-myricx-for-adc-development/ 2023-09-08T11:19:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/veracyte-and-gustave-roussy-announce-collaboration-to-help-biopharmaceutical-companies-accelerate-development-of-novel-cancer-therapies/ 2023-09-08T11:21:20+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/veracyte-logo.jpg http://www.pharmajournalist.com/sandoz-announces-exclusive-deal-to-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering/ 2023-09-12T14:27:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/pfizer-and-biontech-receive-u-s-fda-approval-for-2023-2024-covid-19-vaccine/ 2023-09-12T14:28:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/abcellera-announces-collaboration-with-incyte-to-accelerate-the-discovery-and-development-of-therapeutic-antibodies-in-oncology/ 2023-09-14T09:17:16+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/abcellera.jpg http://www.pharmajournalist.com/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority-review-of-the-new-drug-application-for-resmetirom-for-the-treatment-of-nash-with-liver-fibrosis/ 2023-09-14T09:18:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/takeda-announces-fda-acceptance-of-bla-for-subcutaneous-administration-of-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-crohns-disease/ 2023-09-14T09:20:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/vaxess-announces-9m-in-funding/ 2023-09-14T09:22:18+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/dewpoint-therapeutics-partners-with-chemify-to-apply-groundbreaking-chemistry-ai-to-radically-accelerate-the-discovery-of-molecules-targeting-cancer-and-neurodegeneration/ 2023-09-14T09:24:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/charles-river-and-related-sciences-enter-multi-program-collaboration-to-pursue-ai-enabled-drug-discovery-utilizing-logica/ 2023-09-15T10:08:11+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/astellas-to-invest-more-than-e330-million-in-a-new-state-of-the-art-facility-in-tralee-co-kerry-ireland/ 2023-09-15T10:09:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/peptidream-announces-collaboration-and-license-agreement-with-genentech-for-the-discovery-and-development-of-novel-peptide-radioisotope-drug-conjugates/ 2023-09-20T10:27:34+00:00 https://pharmajournalist.com/wp-content/uploads/2019/06/PeptiDream-Logo.jpg http://www.pharmajournalist.com/beigene-strengthens-global-portfolio-and-regains-full-rights-from-novartis-for-anti-pd-1-antibody-tevimbra-tislelizumab/ 2023-09-20T10:29:14+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/european-commission-approves-pfizers-litfulo-for-adolescents-and-adults-with-severe-alopecia-areata/ 2023-09-20T10:30:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/otsuka-and-astex-announce-that-the-european-commission-has-approved-inaqovi-oral-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-newly-diagnosed-acute-myeloid-leukaemia/ 2023-09-20T10:32:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/fda-accepts-for-priority-review-mercks-supplemental-new-drug-application-for-welireg-belzutifan-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma-rcc/ 2023-09-20T10:33:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/biontech-and-cepi-announce-partnership-to-advance-mrna-mpox-vaccine-development-and-support-cepis-100-days-mission/ 2023-09-20T10:35:33+00:00 https://pharmajournalist.com/wp-content/uploads/2018/07/BioNTech.jpg http://www.pharmajournalist.com/debiopharm-and-sunrock-biopharma-partner-to-advance-antibody-drug-conjugates-for-hard-to-treat-cancers/ 2023-09-22T11:59:28+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Debiopharm-Logo.png http://www.pharmajournalist.com/jura-bio-announces-partnership-with-replay-product-company-syena-to-advance-t-cell-receptor-nk-therapies-in-cancer/ 2023-09-22T12:01:36+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease/ 2023-09-25T12:58:03+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-receives-european-commission-approval-for-enrylaze-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukemia-and-lymphoblastic-lympho/ 2023-09-25T13:00:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/valneva-announces-new-ixiaro-supply-contract-with-the-u-s-government-worth-a-minimum-of-32-million/ 2023-09-25T13:02:33+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/extractables-and-leachables-europe-2023-medical-devices-focus/ 2023-09-26T10:18:52+00:00 https://pharmajournalist.com/wp-content/uploads/2023/09/Pharma-Journalist-Extractables-Leachables-Europe-2023.jpg http://www.pharmajournalist.com/extractables-and-leachables-europe-2023-interactions-of-el/ 2023-09-26T10:20:30+00:00 https://pharmajournalist.com/wp-content/uploads/2023/09/Pharma-Journalist-Extractables-Leachables-Europe-2023.jpg http://www.pharmajournalist.com/extractables-and-leachables-europe-2023-set-to-feature-leading-industry-experts/ 2023-09-26T10:22:17+00:00 https://pharmajournalist.com/wp-content/uploads/2023/09/Pharma-Journalist-Extractables-Leachables-Europe-2023.jpg http://www.pharmajournalist.com/arcturus-therapeutics-and-cystic-fibrosis-foundation-extend-agreement-to-advance-arct-032-an-investigational-messenger-rna-mrna-therapeutic-to-treat-cystic-fibrosis/ 2023-09-27T10:01:39+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/Arcturus-Therapeutics.jpg http://www.pharmajournalist.com/acesion-pharma-closes-oversubscribed-e45m-series-b-financing-round-to-advance-development-of-novel-therapy-for-atrial-fibrillation/ 2023-09-27T10:03:02+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sandoz-receives-european-commission-approval-for-tyruko-natalizumab-first-and-only-biosimilar-for-multiple-sclerosis-in-europe/ 2023-09-27T10:04:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/milliporesigma-to-become-first-provider-to-offer-fully-integrated-mrna-services/ 2023-09-27T10:06:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/MilliporeSigma.jpg http://www.pharmajournalist.com/japans-ministry-of-health-labour-and-welfare-approves-gsks-arexvy-the-countrys-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2023-09-27T10:08:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/odronextamab-bla-for-treatment-of-relapsed-refractory-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dlbcl-accepted-for-fda-priority-review/ 2023-10-02T09:59:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/amicus-therapeutics-announces-fda-approval-and-launch-of-new-treatment-for-pompe-disease/ 2023-10-02T10:01:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/sgc-and-hitgen-announce-research-collaboration-focused-on-dna-encoded-library-based-drug-discovery/ 2023-10-02T10:02:32+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/deka-biosciences-closes-usd-20-million-series-b2-financing-led-by-mpm-bioimpact/ 2023-10-02T10:03:47+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/karuna-therapeutics-submits-new-drug-application-to-u-s-food-and-drug-administration-for-karxt-for-the-treatment-of-schizophrenia/ 2023-10-02T10:05:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/unlocking-tomorrows-solutions-in-chromatography-purify23-conclave-where-science-meets-innovation/ 2023-10-04T12:46:04+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/Purify-2023-Press-Release.png https://pharmajournalist.com/wp-content/uploads/2023/08/Purify-2023-Press-Release.png http://www.pharmajournalist.com/bayer-to-partner-with-twist-bioscience-to-accelerate-drug-discovery/ 2023-10-06T10:26:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/abbvie-exercises-exclusive-right-to-acquire-mitokinin-further-strengthening-neuroscience-pipeline/ 2023-10-06T10:32:12+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/agomab-receives-fda-fast-track-designation-for-agmb-129-in-fibrostenosing-crohns-disease-and-starts-stenova-phase-2a-clinical-trial/ 2023-10-06T10:33:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date/ 2023-10-06T10:36:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/advanz-pharma-and-dimerix-enter-into-an-exclusive-license-agreement-to-commercialise-dmx-200-in-europe-canada-australia-and-new-zealand/ 2023-10-06T10:38:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/sanofi-and-teva-announce-exclusive-collaboration-to-deliver-inflammatory-bowel-disease-treatment/ 2023-10-06T10:40:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/sanofi.jpg http://www.pharmajournalist.com/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-therapies-for-the-treatment-of-neurological-and-muscular-diseases/ 2023-10-06T10:42:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies/ 2023-10-06T11:18:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/salipro-biotech-and-icosagen-launch-antibody-discovery-collaboration/ 2023-10-11T10:17:30+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/biomap-establishes-a-strategic-collaboration-with-sanofi-to-co-develop-ai-modules-to-accelerate-drug-discovery-for-biotherapeutics/ 2023-10-11T10:19:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/bayer-invests-usd-250-million-in-new-cell-therapy-production-facility-in-the-usa/ 2023-10-11T10:20:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/hikma-and-canariabio-sign-exclusive-licensing-agreement-to-bring-oregovomab-to-the-middle-east-and-north-africa/ 2023-10-11T10:22:04+00:00 https://pharmajournalist.com/wp-content/uploads/2020/01/hikma-logo.jpg http://www.pharmajournalist.com/ultimovacs-receives-fda-orphan-drug-designation-for-the-uv1-cancer-vaccine-for-treatment-of-mesothelioma/ 2023-10-11T10:23:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-novartis-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases/ 2023-10-11T10:25:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/hear-from-allogene-poseida-therapeutics-caribou-bio-and-more/ 2023-10-12T13:36:01+00:00 https://pharmajournalist.com/wp-content/uploads/2023/08/Pharma-Journalist-DSCS.png http://www.pharmajournalist.com/mimivax-granted-fast-track-designation-from-fda-for-survaxm-for-newly-diagnosed-glioblastoma/ 2023-10-13T11:38:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-pfizers-braftovi-mektovi-for-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer/ 2023-10-13T11:42:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/almiralls-lebrikizumab-improves-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-ad-in-patients-inadequately-controlled-with-or-ineligible-for-cyclosporine/ 2023-10-13T11:44:42+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/Almirall.jpg http://www.pharmajournalist.com/cellares-announces-expanded-agreement-with-bristol-myers-squibb-to-include-second-car-t-program-in-cellares-technology-adoption-partnership-program/ 2023-10-13T11:46:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/vaxcyte-and-lonza-expand-collaboration-for-global-commercial-manufacturing-of-broad-spectrum-pneumococcal-conjugate-vaccines-pcvs/ 2023-10-17T10:03:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/06/Lonza.jpg http://www.pharmajournalist.com/novo-nordisk-to-acquire-ocedurenone-for-uncontrolled-hypertension-from-kbp-biosciences/ 2023-10-17T10:04:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/legochem-biosciences-enters-worldwide-licensing-agreement-with-glycotope-for-antibody-drug-conjugate-development/ 2023-10-17T10:05:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/gilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases/ 2023-10-18T11:31:37+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/ 2023-10-18T11:32:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/spark-therapeutics.jpg http://www.pharmajournalist.com/ucb-announces-fda-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis/ 2023-10-18T11:35:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/ucb-pharma.jpg http://www.pharmajournalist.com/monte-rosa-therapeutics-announces-strategic-collaboration-with-roche-to-discover-novel-molecular-glue-degraders-targeting-cancer-and-neurological-diseases/ 2023-10-18T11:37:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/antiverse-and-globalbio-inc-extend-collaboration-to-advance-antibody-cancer-therapeutics/ 2023-10-18T11:38:35+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/celebrating-a-decade-of-the-world-adc-awards-winners-announcement/ 2023-10-19T12:35:22+00:00 https://pharmajournalist.com/wp-content/uploads/2023/05/World-ADC-San-Diego-600-x-400-px-1.png http://www.pharmajournalist.com/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-for-the-treatment-of-idh1-mutated-relapsed-or-refractory-r-r-myelodysplastic-syndromes-mds/ 2023-10-25T08:38:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Servier-CDMO.png http://www.pharmajournalist.com/bristol-myers-squibb-announces-fda-breakthrough-therapy-designation-for-investigational-lpa1-antagonist-for-progressive-pulmonary-fibrosis/ 2023-10-25T08:39:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer/ 2023-10-25T08:40:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/alzheimers-drug-discovery-foundation-addf-announces-launch-of-speechdx-the-first-study-to-generate-a-voice-database-paired-with-clinical-data-for-early-detection-of-alzheimers-disease/ 2023-10-25T08:43:38+00:00 https://pharmajournalist.com/wp-content/uploads/2023/10/ADDF_Logo.jpg http://www.pharmajournalist.com/certa-therapeutics-ft011-granted-us-fda-orphan-drug-designation-for-the-treatment-of-systemic-sclerosis/ 2023-10-25T08:45:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/astraveus-awarded-e10-4-million-grant-by-the-french-government-as-part-of-france-2030-investment-plan/ 2023-10-25T08:47:15+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/invo-bioscience-and-naya-biosciences-announce-definitive-merger-agreement-to-establish-expanded-publicly-traded-life-science-company/ 2023-10-25T08:48:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/samsung-biologics-and-kurma-partners-announce-strategic-partnership-for-development-and-manufacturing-of-biologics-for-kurmas-portfolio-companies/ 2023-10-25T08:49:59+00:00 https://pharmajournalist.com/wp-content/uploads/2021/06/Samsung_Biologics_Manufacturing.jpg http://www.pharmajournalist.com/lianbio-enters-into-agreement-with-bristol-myers-squibb-for-mavacamten-in-china-and-other-asian-markets/ 2023-10-25T08:51:53+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/clinical-trial-application-ind-for-bioray-pharmaceuticals-br105-injection-receives-u-s-fda-approval/ 2023-10-25T08:52:55+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-accepts-immunitybios-bla-resubmission-as-complete-and-sets-new-pdufa-date/ 2023-10-27T12:38:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/ 2023-10-27T12:40:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/viiv-healthcare-receives-approval-from-chinas-national-medical-products-administration-nmpa-for-vocabria-cabotegravir-used-in-combination-with-rekambys-rilpivirine-the-first-and-only-c/ 2023-10-27T12:42:12+00:00 https://pharmajournalist.com/wp-content/uploads/2020/07/ViiV-Healthcare.png http://www.pharmajournalist.com/new-data-for-arexvy-gsks-rsv-vaccine-show-potential-to-help-protect-adults-aged-50-to-59-at-increased-risk-for-rsv-disease/ 2023-10-27T12:46:04+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/vect-horus-enters-exclusive-license-agreement-with-novo-nordisk-to-develop-targeted-therapeutics/ 2023-10-31T11:18:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/day-one-announces-fda-acceptance-of-nda-and-priority-review-for-tovorafenib-in-relapsed-or-progressive-pediatric-low-grade-glioma-plgg/ 2023-10-31T11:22:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kite-and-epic-bio-announce-collaboration-to-develop-new-therapies-for-cancer/ 2023-11-01T11:09:00+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989-to-expand-the-development-of-bepirovirsen/ 2023-11-01T11:10:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/fda-approves-novartis-cosentyx-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade/ 2023-11-01T11:11:45+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/sosei-heptares-will-receive-us3-75-million-payment-in-multi-target-partnership/ 2023-11-01T11:14:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-and-broad-institute-extend-cancer-therapy-research-collaboration/ 2023-11-03T09:57:05+00:00 https://pharmajournalist.com/wp-content/uploads/2023/09/Broad-Institute.jpg http://www.pharmajournalist.com/prelude-therapeutics-and-abcellera-enter-partnership-to-develop-first-in-class-precision-antibody-drug-conjugates-in-oncology/ 2023-11-03T09:58:21+00:00 https://pharmajournalist.com/wp-content/uploads/2020/09/abcellera.jpg http://www.pharmajournalist.com/memo-therapeutics-ag-raises-chf-25-million-series-c-financing-to-complete-phase-ii-clinical-development-of-antibkv-for-bkv-infection-in-renal-transplant-patients/ 2023-11-03T10:00:23+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/aldeyra-therapeutics-enters-into-exclusive-option-agreement-with-abbvie-for-license-to-develop-and-commercialize-reproxalap/ 2023-11-03T10:02:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/astrazeneca-announces-collaboration-and-investment-agreement-with-cellectis-to-accelerate-cell-therapy-and-genomic-medicine-ambitions/ 2023-11-03T10:04:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/felzartamab-granted-breakthrough-therapy-designation-by-u-s-food-and-drug-administration-fda-for-primary-membranous-nephropathy-pmn/ 2023-11-03T10:06:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/landmark-bio-signs-multi-year-agreement-to-manufacture-galapagos-oncology-car-t-cell-therapy-clinical-programs-at-the-point-of-care/ 2023-11-07T11:15:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/nrx-pharmaceuticals-and-nephron-pharmaceuticals-announce-joint-agreement-to-develop-intravenous-ketamine-to-treat-suicidal-depression/ 2023-11-07T11:17:26+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/agenda-launched-the-6th-chronic-kidney-disease-ckd-drug-development-summit/ 2023-11-09T14:36:25+00:00 https://pharmajournalist.com/wp-content/uploads/2023/11/CKD-Pharma-J.png http://www.pharmajournalist.com/takeda-receives-u-s-fda-approval-of-fruzaqla-fruquintinib-for-previously-treated-metastatic-colorectal-cancer/ 2023-11-09T14:39:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/ascidian-therapeutics-raises-40-million-in-series-a-extension-financing-from-apple-tree-partners-and-appoints-michael-ehlers-as-interim-ceo/ 2023-11-09T14:42:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/bayer-and-recursion-focus-research-collaboration-on-oncology/ 2023-11-10T11:50:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/takedas-adzynma-adamts13-recombinant-krhn-approved-by-u-s-fda-as-the-first-and-only-recombinant-adamts13-enzyme-replacement-therapy-for-the-treatment-of-congenital-thrombotic-thrombocytop/ 2023-11-10T11:59:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/astrazeneca-licenses-novel-agent-for-the-treatment-of-cardiometabolic-conditions-and-obesity/ 2023-11-10T12:01:41+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/valneva-announces-fda-approval-of-worlds-first-chikungunya-vaccine-ixchiq/ 2023-11-10T12:05:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/orsobio-announces-60m-series-a-financing-to-advance-metabolic-portfolio-for-the-treatment-of-obesity-and-associated-disorders/ 2023-11-10T12:08:00+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/almirall-and-absci-announce-ai-drug-discovery-partnership-to-rapidly-develop-novel-treatments-for-dermatological-diseases/ 2023-11-15T10:57:39+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/Almirall.jpg http://www.pharmajournalist.com/mbrace-therapeutics-raises-85-million-series-b-financing-to-advance-oncology-pipeline-of-innovative-antibody-drug-conjugate-candidates/ 2023-11-15T10:58:56+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591/ 2023-11-15T11:01:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/autifony-announces-exclusive-global-license-and-collaboration-agreement-with-jazz-pharmaceuticals-on-two-ion-channel-targets-for-neurological-disorders/ 2023-11-15T11:03:14+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/teva-and-royalty-pharma-collaborate-to-further-accelerate-olanzapine-lai-program/ 2023-11-15T11:05:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/vectory-raises-e129-million-138-million-series-a-financing-to-advance-vectorized-antibody-programs-in-neurodegenerative-diseases/ 2023-11-15T11:07:10+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/kesin-pharma-announces-fda-approval-and-u-s-availability-of-likmez-metronidazole-oral-suspension/ 2023-11-15T11:09:22+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/kite-and-arcellx-announce-expansion-in-strategic-partnership/ 2023-11-16T10:47:06+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/Kite-Pharma.jpg http://www.pharmajournalist.com/astellas-to-acquire-propella-therapeutics/ 2023-11-16T10:49:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astellas.jpg http://www.pharmajournalist.com/lenz-therapeutics-and-graphite-bio-announce-merger-agreement/ 2023-11-16T10:50:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/fda-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-gej/ 2023-11-17T12:15:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/versameb-ag-announces-fda-clearance-of-ind-application-for-vmb-100-in-the-treatment-of-stress-urinary-incontinence/ 2023-11-17T12:16:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/micron-biomedical-receives-23-6-million-to-accelerate-commercial-manufacturing-of-needle-free-vaccines-and-to-help-eradicate-measles/ 2023-11-17T12:21:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/astrazeneca-launches-evinova-a-health-tech-business-to-accelerate-innovation-across-the-life-sciences-sector-the-delivery-of-clinical-trials-and-better-health-outcomes/ 2023-11-20T11:09:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma/ 2023-11-20T11:11:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/Beigene.jpg http://www.pharmajournalist.com/truqap-capivasertib-plus-faslodex-approved-in-the-us-for-patients-with-advanced-hr-positive-breast-cancer/ 2023-11-20T11:13:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/ 2023-11-22T09:07:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/Genentech-Image.jpg http://www.pharmajournalist.com/merck-to-acquire-caraway-therapeutics-inc/ 2023-11-22T09:09:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/janssen-submits-supplemental-biologics-license-application-to-u-s-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-plus-chemotherapy-for-the-treatment-of-patients-with-egfr-mutated-non-small-cell/ 2023-11-22T09:11:46+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Janssen-Pharma-Logo.jpg http://www.pharmajournalist.com/fda-grants-orphan-drug-designation-to-neoimmunetechs-nt-i7-for-the-treatment-of-acute-radiation-syndrome/ 2023-11-22T09:13:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/chiesi-group-signed-a-license-agreement-with-haisco-pharmaceutical-to-develop-manufacture-and-commercialise-a-novel-reversible-dipeptidyl-peptidase-1-inhibitor-for-bronchiectasis/ 2023-11-22T09:15:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/boehringer-ingelheim-expands-immuno-oncology-portfolio-with-the-acquisition-of-bacterial-cancer-therapy-specialist-t3-pharma/ 2023-11-23T13:02:01+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/sk-bioscience-and-hilleman-laboratories-announce-joint-development-of-second-generation-zaire-ebola-virus-vaccine/ 2023-11-23T13:06:04+00:00 https://pharmajournalist.com/wp-content/uploads/2023/11/SK-bioscience.png http://www.pharmajournalist.com/vivodyne-announces-38-million-seed-financing-led-by-khosla-ventures-to-develop-lab-grown-human-organs/ 2023-11-23T13:07:44+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/european-commission-approves-kaftrio-in-combination-with-ivacaftor-for-the-treatment-of-children-with-cystic-fibrosis-ages-2-through-5/ 2023-11-24T12:11:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/boehringer-ingelheim-receives-approval-for-senvelgo-in-europe-the-first-oral-liquid-medication-for-diabetic-cats/ 2023-11-24T12:26:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/boehringer-ingelheim.jpg http://www.pharmajournalist.com/prism-biolab-and-lilly-enter-into-a-drug-discovery-collaboration-on-a-protein-protein-interaction-target/ 2023-11-30T00:04:43+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/lilly.jpg http://www.pharmajournalist.com/amacathera-closes-series-a-extension-to-advance-clinical-development-of-long-acting-localized-non-opioid-therapeutics-to-improve-post-surgery-patient-care/ 2023-11-30T00:06:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/aro-biotherapeutics-secures-41-5m-series-b-financing/ 2023-11-30T00:07:33+00:00 https://pharmajournalist.com/wp-content/uploads/2020/10/Aro-Biotherapeutics-Logo.jpg http://www.pharmajournalist.com/novavaxs-updated-protein-based-covid-19-vaccine-now-an-option-for-all-194-member-states-of-the-world-health-organization/ 2023-11-30T00:10:29+00:00 https://pharmajournalist.com/wp-content/uploads/2020/03/NOVAVAX.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-ibm-collaborate-to-advance-generative-ai-and-foundation-models-for-therapeutic-antibody-development/ 2023-11-30T00:12:42+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/abbvie-announces-fda-and-ema-updates-for-epcoritamab-epkinly-tepkinly-for-the-treatment-of-relapsed-refractory-follicular-lymphoma/ 2023-11-30T00:15:13+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/genelux-corporation-receives-fda-fast-track-designation-for-olvi-vec-in-platinum-resistant-refractory-ovarian-cancer/ 2023-11-30T00:16:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/teva-completes-closing-of-exclusive-collaboration-deal-to-deliver-inflammatory-bowel-disease-treatment/ 2023-12-01T11:59:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/TEVA-Pharma.jpg http://www.pharmajournalist.com/abbvie-to-acquire-immunogen-including-its-flagship-cancer-therapy-elahere-mirvetuximab-soravtansine-gynx-expanding-solid-tumor-portfolio/ 2023-12-01T12:02:27+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-combination-with-cisplatin-based-chemotherapy-for-the-first-line-treatment-of-adult-patients-with-u/ 2023-12-06T11:37:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/fda-grants-priority-review-of-immunogens-supplemental-biologics-license-application-for-elahere-mirvetuximab-soravtansine-gynx-in-platinum-resistant-ovarian-cancer/ 2023-12-06T11:38:31+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Immunogen-Logo.png http://www.pharmajournalist.com/aqemia-announces-a-major-multi-year-collaboration-of-140-million-with-sanofi/ 2023-12-06T11:39:41+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/vanda-pharmaceuticals-announces-that-fda-accepts-new-drug-application-for-tradipitant-for-the-treatment-of-gastroparesis/ 2023-12-06T11:41:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbisko-therapeutics-announced-the-entry-into-a-licensing-agreement-for-pimicotinib-absk021-with-merck/ 2023-12-06T11:42:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/2024-agenda-revealed-2nd-next-generation-ophthalmic-drug-delivery-summit/ 2023-12-06T11:46:45+00:00 https://pharmajournalist.com/wp-content/uploads/2023/12/41017-Pharma-Journalist-event-listing-banner.jpg http://www.pharmajournalist.com/2024-agenda-revealed-4th-wet-amd-diabetic-eye-disease-drug-development-summit/ 2023-12-07T11:52:58+00:00 https://pharmajournalist.com/wp-content/uploads/2023/12/Wet-AMD-Banner.png http://www.pharmajournalist.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/ 2023-12-08T10:38:36+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/solid-biosciences-receives-fda-fast-track-designation-for-duchenne-muscular-dystrophy-gene-therapy-sgt-003/ 2023-12-08T10:39:43+00:00 https://pharmajournalist.com/wp-content/uploads/2023/01/solid-biosciences.jpg http://www.pharmajournalist.com/ipsen-confirms-fda-grants-priority-review-for-new-drug-application-for-elafibranor-for-the-treatment-of-rare-cholestatic-liver-disease-pbc/ 2023-12-08T10:41:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/synplogen-and-ginkgo-bioworks-announce-plans-to-accelerate-global-dna-manufacturing-and-gene-therapy-platform-services-in-japan/ 2023-12-08T10:43:10+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/arvinas-and-pfizer-announce-interim-data-from-phase-1b-trial-of-vepdegestrant-in-combination-with-palbociclib-ibrance-and-plans-to-expand-vepdegestrant-development-program/ 2023-12-08T10:44:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/bristol-myers-squibbs-abecma-becomes-first-car-t-approved-for-use-in-earlier-lines-of-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma-in-japan/ 2023-12-08T10:46:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/abbvie-and-bighat-biosciences-announce-research-collaboration-to-leverage-artificial-intelligence-and-machine-learning-to-discover-next-generation-therapeutic-antibodies/ 2023-12-08T10:47:47+00:00 https://pharmajournalist.com/wp-content/uploads/2018/04/abbvie-logo.jpg http://www.pharmajournalist.com/alkermes-plc-announces-agreement-to-sell-athlone-ireland-facility-to-novo-nordisk/ 2023-12-14T22:31:12+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/abbisko-therapeutics-announces-that-fda-has-granted-fast-track-designation-for-its-csf-1r-inhibitor-pimicotinib-absk021/ 2023-12-14T22:32:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-amgens-tarlatamab-application-for-advanced-small-cell-lung-cancer/ 2023-12-14T22:33:30+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/amgen.jpg http://www.pharmajournalist.com/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-myasthenia-gravis/ 2023-12-14T22:34:29+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ironwood-announces-the-completion-of-squeeze-out-merger-with-vectivbio/ 2023-12-14T22:35:45+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ironwood-Pharmaceuticals-Logo.png http://www.pharmajournalist.com/depixus-announces-strategic-collaboration-with-daiichi-sankyo-to-use-magna-technology-to-accelerate-rna-targeted-drug-discovery/ 2023-12-14T22:38:19+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/freya-biosciences-announces-38-million-funding-in-one-of-the-largest-series-a-raises-to-advance-womens-reproductive-immunotherapies/ 2023-12-14T22:39:32+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/japans-ministry-of-health-labour-and-welfare-accepts-arexvy-rsv-vaccine-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2023-12-14T22:40:44+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/pfizer-receives-all-required-regulatory-approvals-to-complete-the-acquisition-of-seagen/ 2023-12-14T22:42:17+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data/ 2023-12-14T22:43:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/codexis-and-aldevron-enter-exclusive-licensing-agreement-for-codex-hicap-rna-polymerase/ 2023-12-14T22:46:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/almirall-and-etherna-enter-into-a-multi-target-alliance-to-develop-mrna-based-therapies-in-medical-dermatology/ 2023-12-14T22:47:56+00:00 https://pharmajournalist.com/wp-content/uploads/2018/12/Almirall.jpg http://www.pharmajournalist.com/teva-and-biolojic-design-announce-exclusive-license-agreement-for-the-development-of-a-therapeutic-antibody-for-atopic-dermatitis-and-asthma/ 2023-12-15T13:08:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/TEVA-Pharma.jpg http://www.pharmajournalist.com/ocelot-bio-receives-fda-orphan-drug-designation-for-oce-205-for-the-treatment-of-ascites/ 2023-12-21T13:33:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/ 2023-12-21T13:35:18+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/ 2023-12-21T13:37:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-xolair-omalizumab-for-children-and-adults-with-food-allergies-based-on-positive-national-institutes-of-health-phase-iii-study-results/ 2023-12-21T13:39:47+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults/ 2023-12-21T13:41:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/gilead-and-compugen-announce-exclusive-license-agreement-for-novel-pre-clinical-immunotherapy-program/ 2023-12-21T13:43:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/european-medicines-agency-validates-bristol-myers-squibbs-application-for-repotrectinib-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-and-ntrk-p/ 2024-01-03T12:58:49+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/medilink-therapeutics-announces-worldwide-collaboration-and-license-agreement-with-roche-to-develop-next-generation-antibody-drug-conjugate-in-oncology/ 2024-01-03T13:00:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/immunitybio-announces-320-million-investment-by-oberland-capital-with-210-million-funded-at-closing-bringing-total-financing-in-2023-to-850-million/ 2024-01-03T13:01:41+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants/ 2024-01-03T13:02:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/oragenics-completes-acquisition-of-odyssey-healths-neurological-assets/ 2024-01-03T13:04:11+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/elpiscience-and-astellas-enter-into-research-collaboration-and-license-agreement-for-novel-bispecific-macrophage-engager/ 2024-01-03T13:07:24+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astellas.jpg http://www.pharmajournalist.com/boehringer-ingelheim-and-3t-biosciences-enter-into-a-second-partnership-to-develop-next-generation-cancer-immunotherapies/ 2024-01-05T09:16:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/Boehringer-Ingelheim.jpg http://www.pharmajournalist.com/avistone-biotechnology-announces-closing-of-series-b-financing/ 2024-01-05T09:18:10+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/medivirs-licensee-tango-therapeutics-has-dosed-the-first-patient-with-tng348-a-novel-usp1-inhibitor-in-a-phase-1-2-clinical-study/ 2024-01-05T09:19:46+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.jpg http://www.pharmajournalist.com/esperion-and-daiichi-sankyo-europe-announce-125-million-amendment-to-their-collaboration-including-resolution-of-pending-litigation/ 2024-01-05T09:21:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/Daiichi-Pharma.jpg http://www.pharmajournalist.com/agios-announces-phase-3-energize-study-of-mitapivat-met-primary-endpoint-and-both-key-secondary-endpoints-in-adults-with-non-transfusion-dependent-alpha-or-beta-thalassemia/ 2024-01-05T09:23:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/clinical-trials.png http://www.pharmajournalist.com/innate-pharma-announces-u-s-fda-lifts-partial-clinical-hold-on-lacutamab-clinical-program/ 2024-01-05T09:25:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype/ 2024-01-11T10:30:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/myrobalan-therapeutics-completes-series-a-financing-of-24-million-to-develop-potentially-first-in-class-cns-therapeutics-with-restorative-potential/ 2024-01-11T10:31:52+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/gsk-enters-agreement-to-acquire-aiolos-bio/ 2024-01-11T10:33:20+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/gsk.jpg http://www.pharmajournalist.com/vertex-announces-approval-of-first-crispr-cas9-gene-edited-therapy-casgevy-for-the-treatment-of-sickle-cell-disease-scd-and-transfusion-dependent-beta-thalassemia-tdt-in-kingdom-of-saud/ 2024-01-11T10:34:35+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/ 2024-01-11T10:36:32+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/ 2024-01-11T10:38:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/merck.jpg http://www.pharmajournalist.com/johnson-johnson-to-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-to-transform-the-treatment-of-cancer/ 2024-01-11T10:40:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/basilea-announces-acquisition-of-preclinical-antibiotics-program-from-spexis/ 2024-01-16T09:41:41+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/vertex-announces-fda-approval-of-casgevy-exagamglogene-autotemcel-for-the-treatment-of-transfusion-dependent-beta-thalassemia/ 2024-01-17T11:10:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/fda-approves-takedas-hyqvia-as-maintenance-therapy-in-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp/ 2024-01-17T11:12:28+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/european-commission-approves-roches-tecentriq-sc-the-eus-first-pd-l1-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types/ 2024-01-17T11:18:23+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/roche-pharma.jpg http://www.pharmajournalist.com/bridgebio-pharma-secures-up-to-1-25-billion-of-capital-from-blue-owl-and-cpp-investments-to-accelerate-the-development-and-launch-of-genetic-medicines/ 2024-01-19T12:32:34+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/verastem-oncology-granted-fast-track-designation-for-combination-of-avutometinib-and-sotorasib-for-the-treatment-of-kras-g12c-mutant-non-small-cell-lung-cancer-nsclc/ 2024-01-19T12:34:11+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/halozyme-announces-argenx-received-approval-in-japan-for-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-co-formulated-with-enhanze-for-generalized-myasthenia-gravis/ 2024-01-19T12:36:09+00:00 https://pharmajournalist.com/wp-content/uploads/2019/05/Halozyme-Logo.png http://www.pharmajournalist.com/sanofi-to-acquire-inhibrx-inc-adding-potential-best-in-class-rare-disease-asset-for-alpha-1-antitrypsin-deficiency-to-pipeline/ 2024-01-23T11:48:07+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/the-european-commission-grants-orphan-drug-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis/ 2024-01-23T11:50:23+00:00 https://pharmajournalist.com/wp-content/uploads/2020/08/European-Commission.jpg http://www.pharmajournalist.com/sandoz-announces-agreement-to-acquire-cimerli-business-from-coherus-strengthening-position-in-us-market/ 2024-01-23T11:51:57+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-progressive-multiple-sclerosis/ 2024-01-23T11:53:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/fda-grants-full-approval-for-balversa-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations/ 2024-01-23T11:55:07+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/dupixent-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis-eoe/ 2024-01-26T12:27:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/travere-therapeutics-announces-licensing-agreement-with-renalys-pharma-to-develop-and-commercialize-sparsentan-in-japan-south-korea-taiwan-and-southeast-asian-nations/ 2024-01-26T12:37:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/agreement-signing.png http://www.pharmajournalist.com/repare-therapeutics-announces-achievement-of-40-million-roche-clinical-milestone-payment/ 2024-01-26T12:39:41+00:00 https://pharmajournalist.com/wp-content/uploads/2019/02/Repare-Therapeutics-Logo.jpg http://www.pharmajournalist.com/evaxion-to-develop-tailored-novel-cancer-vaccines-based-upon-a-new-untapped-source-of-ai-discovered-targets/ 2024-01-26T12:42:39+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/vertex-announces-positive-results-from-the-vx-548-phase-3-program-for-the-treatment-of-moderate-to-severe-acute-pain/ 2024-01-31T10:38:21+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Vertex.jpg http://www.pharmajournalist.com/regeneron-announces-formation-of-regeneron-cell-medicines-with-the-acquisition-of-2seventy-bio-platforms-and-preclinical-and-clinical-programs/ 2024-01-31T10:41:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/gsks-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2024-01-31T10:43:35+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/aqemia-boosts-series-a-funding-to-e60m-to-accelerate-on-its-proprietary-therapeutic-pipeline/ 2024-01-31T10:46:26+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/gilead-and-arcus-announce-amended-collaboration-and-equity-investment/ 2024-01-31T10:48:13+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/takedas-gammagard-liquid-approved-by-fda-for-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp/ 2024-01-31T10:50:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours/ 2024-01-31T10:52:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/gsks-rsv-vaccine-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2024-02-07T11:50:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/novartis-to-strengthen-oncology-pipeline-with-agreement-to-acquire-morphosys-ag-for-eur-68-per-share-or-an-aggregate-of-eur-2-7bn-in-cash/ 2024-02-07T11:51:50+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/novartis.jpg http://www.pharmajournalist.com/johnson-johnson-reports-positive-topline-results-for-nipocalimab-from-a-phase-3-pivotal-study-in-generalized-myasthenia-gravis-gmg-and-a-phase-2-study-in-sjogrens-disease-sjd/ 2024-02-07T11:53:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/novo-nordisk-to-acquire-three-fill-finish-sites-from-novo-holdings-a-s-in-connection-with-the-catalent-inc-transaction/ 2024-02-07T11:55:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/novo-nordisk-logo.jpg http://www.pharmajournalist.com/incyte-gains-exclusive-global-development-and-commercialization-rights-to-tafasitamab-monjuvi/ 2024-02-07T11:57:06+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/incyte-logo.jpg http://www.pharmajournalist.com/valneva-announces-sale-of-priority-review-voucher-for-103-million/ 2024-02-07T11:58:59+00:00 https://pharmajournalist.com/wp-content/uploads/2019/07/Valneva-Logo.png http://www.pharmajournalist.com/telix-signs-agreement-to-acquire-qsam-biosciences-and-its-bone-cancer-targeting-platform/ 2024-02-08T12:45:44+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/jazz-pharmaceuticals-enters-definitive-agreement-with-redx-pharma-to-acquire-global-rights-to-kras-inhibitor-program/ 2024-02-08T12:46:58+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/jazz-pharmaceuticals.jpg http://www.pharmajournalist.com/veru-announces-fda-clearance-of-ind-application-to-initiate-phase-2b-clinical-trial-with-enobosarm-to-treat-muscle-loss-associated-with-weight-loss-drugs/ 2024-02-08T12:48:10+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/bristol-myers-squibb-announces-acceptance-of-u-s-and-eu-regulatory-filings-for-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-in-resectable-non-small-cell-lun/ 2024-02-08T12:49:33+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/gene-therapy-advancements-surge-leading-to-the-return-of-the-7th-gene-therapy-for-rare-disorders-summit/ 2024-02-08T12:57:40+00:00 https://pharmajournalist.com/wp-content/uploads/2024/02/41133-GTxRD.png http://www.pharmajournalist.com/abbvie-completes-acquisition-of-immunogen/ 2024-02-13T10:40:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/saama-and-pfizer-expand-agreement-to-integrate-ai-driven-data-solutions-across-rd-portfolio/ 2024-02-13T10:42:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/pfizer.jpg http://www.pharmajournalist.com/fda-approves-takedas-eohilia-budesonide-oral-suspension-the-first-and-only-oral-treatment-in-the-u-s-for-eosinophilic-esophagitis-eoe/ 2024-02-13T10:44:16+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/Takeda-Office-Canada.jpg http://www.pharmajournalist.com/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/ 2024-02-13T10:46:15+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/alys-pharmaceuticals-launches-with-100m-financing-from-medicxi-to-advance-immuno-dermatology-focused-pipeline/ 2024-02-13T10:47:22+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/6th-ckd-drug-development-summit-countdown-begins/ 2024-02-13T11:05:50+00:00 https://pharmajournalist.com/wp-content/uploads/2024/02/40629-Featured-Image.png https://pharmajournalist.com/wp-content/uploads/2024/02/40629-Featured-Image.png http://www.pharmajournalist.com/latigo-biotherapeutics-debuts-with-135-million-series-a-financing-to-develop-non-opioid-pain-medicines/ 2024-02-15T11:25:39+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/vantai-enters-collaboration-with-bristol-myers-squibb-to-accelerate-molecular-glue-drug-discovery-through-artificial-intelligence/ 2024-02-15T11:27:51+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/gsk-completes-acquisition-of-aiolos-bio/ 2024-02-15T11:29:05+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/gsk.jpg http://www.pharmajournalist.com/ipsens-onivyde-regimen-a-potential-new-standard-of-care-first-line-therapy-in-metastatic-pancreatic-adenocarcinoma-approved-by-fda/ 2024-02-15T11:31:26+00:00 https://pharmajournalist.com/wp-content/uploads/2018/06/Ipsen-Group-Image.jpg http://www.pharmajournalist.com/almirall-licenses-an-anti-il-21-monoclonal-antibody-from-novo-nordisk-to-develop-it-as-a-first-in-class-agent-in-dermatology/ 2024-02-19T11:02:34+00:00 https://pharmajournalist.com/wp-content/uploads/2017/11/Almirall_Plant_Reinbek.jpg http://www.pharmajournalist.com/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer/ 2024-02-19T11:04:26+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/sarepta-therapeutics-announces-u-s-fda-acceptance-of-an-efficacy-supplement-to-expand-the-elevidys-indication/ 2024-02-19T11:06:06+00:00 https://pharmajournalist.com/wp-content/uploads/2018/09/Sarepta-Therapeutics.jpg http://www.pharmajournalist.com/sibeprenlimab-receives-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-immunoglobulin-a-nephropathy/ 2024-02-19T11:07:48+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/otsuka-europe.jpg http://www.pharmajournalist.com/japan-first-in-the-world-to-approve-dupixent-for-chronic-spontaneous-urticaria-csu/ 2024-02-19T11:09:17+00:00 https://pharmajournalist.com/wp-content/uploads/2018/01/Sanofi.jpg http://www.pharmajournalist.com/linvoseltamab-bla-for-treatment-of-relapsed-refractory-multiple-myeloma-accepted-for-fda-priority-review/ 2024-02-22T13:01:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/08/regeneron.jpg http://www.pharmajournalist.com/charles-river-and-wheeler-bio-complete-agreement-to-accelerate-the-journey-from-discovery-and-cmc-development-to-manufacturing/ 2024-02-22T13:02:57+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Charles-River.jpeg http://www.pharmajournalist.com/pepgen-receives-u-s-fda-fast-track-designation-for-pgn-edodm1-for-the-treatment-of-myotonic-dystrophy-type-1/ 2024-02-22T13:04:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-and-tentarix-announce-collaboration-to-develop-conditionally-active-multi-specific-biologics-for-oncology-and-immunology/ 2024-02-23T11:27:30+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/immunocore-announces-clinical-trial-collaboration-and-supply-agreement-with-bristol-myers-squibb-to-evaluate-imc-f106c-prame-hla-a02-in-combination-with-nivolumab-in-its-registrational-phase-3-first/ 2024-02-23T11:29:25+00:00 https://pharmajournalist.com/wp-content/uploads/2017/02/abzena-clinical.jpg http://www.pharmajournalist.com/acquisition-of-gracell-completed/ 2024-02-23T11:30:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/astrazeneca-1.jpg http://www.pharmajournalist.com/wuxi-advanced-therapies-receives-fda-approval-to-manufacture-iovances-amtagvi-lifileucel-for-advanced-melanoma/ 2024-02-23T11:33:40+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/ligand-partner-eisai-receives-approval-in-japan-for-injection-formulation-of-antiepileptic-drug-fycompa/ 2024-02-23T11:35:55+00:00 https://pharmajournalist.com/wp-content/uploads/2020/04/handshake.jpg http://www.pharmajournalist.com/lutris-pharma-receives-fda-orphan-drug-designation-for-lut014-for-the-treatment-of-egfri-induced-acneiform-rash/ 2024-03-01T06:20:54+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/FDA.jpg http://www.pharmajournalist.com/abbvie-and-ose-immunotherapeutics-announce-partnership-to-develop-a-novel-monoclonal-antibody-for-the-treatment-of-chronic-inflammation/ 2024-03-01T06:22:18+00:00 https://pharmajournalist.com/wp-content/uploads/2018/02/Abbvie.jpg http://www.pharmajournalist.com/amneal-enters-into-exclusive-european-licensing-agreement-with-zambon-biotech-for-ipx203/ 2024-03-01T06:24:19+00:00 https://pharmajournalist.com/wp-content/uploads/2019/04/Amneal-Pharma.jpg http://www.pharmajournalist.com/telix-expands-u-s-development-and-manufacturing-infrastructure-with-acquisition-of-isotherapeutics/ 2024-03-01T06:26:15+00:00 https://pharmajournalist.com/wp-content/uploads/2018/10/Telix-Pharmaceuticals-Logo.jpg http://www.pharmajournalist.com/fda-approves-expanded-indication-for-gileads-biktarvy-to-treat-people-with-hiv-with-suppressed-viral-loads-pre-existing-resistance/ 2024-03-01T06:27:38+00:00 https://pharmajournalist.com/wp-content/uploads/2017/12/gilead1.jpg http://www.pharmajournalist.com/bristol-myers-squibb-completes-acquisition-of-rayzebio-adding-differentiated-actinium-based-radiopharmaceutical-platform/ 2024-03-01T06:31:00+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/bayer-receives-u-s-fda-breakthrough-therapy-designation-for-bay-2927088-for-non-small-cell-lung-cancer-harboring-her2-activating-mutations/ 2024-03-01T06:33:27+00:00 https://pharmajournalist.com/wp-content/uploads/2017/10/bayer.jpg http://www.pharmajournalist.com/two-datopotamab-deruxtecan-applications-validated-in-the-eu-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-or-hr-positive-her2-negative-breast-cancer/ 2024-03-04T22:32:56+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/astrazeneca.jpg http://www.pharmajournalist.com/sandoz-acquires-cimerli-business-from-coherus-further-building-biosimilar-and-ophthalmology-leadership-in-us-market/ 2024-03-04T22:37:08+00:00 https://pharmajournalist.com/wp-content/uploads/2017/05/sandoz.jpg http://www.pharmajournalist.com/fogpharma-announces-145-million-financing-to-support-ongoing-clinical-development-of-fog-001-and-accelerate-helicon-peptide-portfolio/ 2024-03-04T22:53:06+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/johnson-johnson-completes-acquisition-of-ambrx/ 2024-03-08T12:50:40+00:00 https://pharmajournalist.com/wp-content/uploads/2018/11/Johnson-Johnson-Logo.png http://www.pharmajournalist.com/fda-approves-opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma/ 2024-03-08T12:53:09+00:00 https://pharmajournalist.com/wp-content/uploads/2017/04/bristol-myers-squibb.jpg http://www.pharmajournalist.com/sionna-therapeutics-announces-182-million-series-c-financing-to-advance-clinical-development-of-novel-small-molecules-in-cystic-fibrosis/ 2024-03-08T12:54:24+00:00 https://pharmajournalist.com/wp-content/uploads/2021/03/Finance.jpg http://www.pharmajournalist.com/sk-bioscience-breaks-ground-on-manufacturing-facility-expansion-for-extending-product-pipeline/ 2024-03-08T12:56:58+00:00 https://pharmajournalist.com/wp-content/uploads/2024/03/SK_bioscience_image.jpg https://pharmajournalist.com/wp-content/uploads/2024/03/SK_bioscience_image.jpg